Document:

Collaboration Agreement - Gen-Probe International

 Exhibit 10.7 
 Confidential Treatment Requested by 
 Pacific Biosciences of California, Inc.

 COLLABORATION AGREEMENT 
 between 
 PACIFIC BIOSCIENCES OF CALIFORNIA, INC. 

and 
 GEN-PROBE
INCORPORATED 
 Dated as of June 15, 2010 

 COLLABORATION AGREEMENT 

THIS COLLABORATION AGREEMENT (the “Agreement”) is entered into between Pacific Biosciences of California, Inc., a Delaware
corporation (“PacBio”), having a place of business at 1505 Adams Drive, Menlo Park, California 94025 and Gen-Probe Incorporated, a Delaware corporation (“Gen-Probe”), having a place of business at 10210 Genetic Center Drive, San
Diego, California 92121. PacBio and Gen-Probe may each sometimes be referred to herein as a “party” and collectively as the “parties.” 
 RECITALS 
 WHEREAS, the parties each recognize the potential mutual benefit in
cooperating in the potential development of instrumentation and related products for the Diagnostics (as defined herein) market (the “Collaboration”). 
 WHEREAS, PacBio owns or has proprietary rights and expertise in Sample Preparation Systems (as defined herein) and Third Generation Sequencing Systems (as defined herein) and associated technologies.

 WHEREAS, Gen-Probe owns or has proprietary rights and expertise in the areas of Diagnostics workflow, systems integration,
and Sample Preparation Systems, and expertise in the areas of clinical product development and regulatory clearances. 

WHEREAS, the parties desire to collaborate toward the joint development of Products (each as defined herein) on the terms and subject to
the conditions of this Agreement. 
 WHEREAS, the parties intend to enter subsequently into one or more Preferred Partnership
Agreements (as defined herein), if warranted, to collaborate toward the further development, regulatory clearance and commercialization of Products in the Field, including Products developed under the terms of this Agreement. 

WHEREAS, in connection herewith, the parties are also entering into a stock purchase agreement (the “Stock Purchase
Agreement”), pursuant to which Gen-Probe shall purchase shares of PacBio’s Series F preferred stock for an aggregate purchase price equal to $50 million. 
 NOW, THEREFORE, in consideration of the foregoing premises and the mutual covenants set forth below, the parties hereby agree as follows: 

ARTICLE 1 

DEFINITIONS 
 For
purposes of this Agreement, the terms defined in this Article 1 shall have the respective meanings set forth below: 
 1.1
“Action” shall have the meaning set forth in Section 7.10. 
  

 1 

 1.2 “Affiliate” shall mean, with respect to any Person, any other Person which
directly or indirectly controls, is controlled by, or is under common control with, such Person. A Person shall be regarded as in control of another Person if it owns, or directly or indirectly controls, more than fifty percent (50%) of the voting
stock or other ownership interest of the other Person (or such lesser percentage as is the maximum percentage permitted under applicable law for foreign ownership where control is exercised by contract or otherwise), or if it directly or indirectly
possesses the power to direct or cause the direction of the management and policies of the other Person by any means whatsoever (provided, however, that in the case of an entity organized under Section 501(c)(3) of the Internal Revenue Code,
the direct or indirect power of a party to direct or cause the direction of the management and policies of the entity shall not in and of itself cause the entity to be deemed an Affiliate for purposes of this Agreement). 

1.3 “Agreement” shall have the meaning set forth in the Preamble hereto. 1.4 “Change of Control” shall mean, with
respect to a party, any of the following: (a) the sale or disposition of all or substantially all of the assets of such party or its direct or indirect parent corporation to a Third Party, (b) the acquisition by a Third Party which constitutes
one person, as such term is used in Section 13(d) and 14(d) of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), together with any such person’s “affiliates” or “associates,” as such terms
are defined in the Exchange Act, other than an employee benefit plan (or related trust) sponsored or maintained by such party or any of its Affiliates, of more than 50% of the outstanding shares of voting capital stock of such party or its direct or
indirect parent corporation, or (c) the merger or consolidation of such party or its direct or indirect parent corporation with or into another corporation, other than, in the case of this clause (c), an acquisition or a merger or consolidation of
such party or its direct or indirect parent corporation in which holders of shares of the voting capital stock of such party or its direct or indirect parent corporation, as the case may be, immediately prior to the acquisition, merger or
consolidation will have at least fifty percent (50%) of the ownership of voting capital stock of the acquiring Third Party or the surviving corporation in such merger or consolidation, as the case may be, immediately after the merger or
consolidation. 
 1.5 “Collaboration” shall have the meaning set forth in the recitals. 

1.6 “Commercially Available” shall mean, with respect to a product and a party, that such product is made available by such
party or its Affiliate to a Third Party through (i) commercial sale or transfer of such product (including pursuant to an OEM supply arrangement) or (ii) commercial sale of a service utilizing such product. 

1.7 “Commercially Reasonable Efforts” shall mean the application of efforts and available resources, not materially
inconsistent with the exercise of prudent scientific and business judgment. “Commercially Reasonable Efforts” shall be deemed to have occurred if a reasonably prudent business person would have exerted similar efforts after taking into
account, among other factors, in no particular order, and with no particular relative weighting: the industry; the relative market timing, potential, and size, and the stage in the development or life of, the relevant product(s) and/or services, and
the dependencies and other interrelationships there between; the size and stage in the development or life of the entity; the current and projected future availability of sufficient capital and other resources, and the terms on which such resources
are or will be available; and/or any other factor(s) actually considered and/or that a reasonably prudent business person would consider under similar 

 

 2 

 
circumstances. Subject to and without limiting the foregoing, “Commercially Reasonable Efforts” shall require the applicable party to: (i) promptly assign responsibilities for
activities for which it is responsible to specific employee(s) who are held accountable for the progress, monitoring and completion of such activities, (ii) set and consistently seek to achieve meaningful objectives for carrying out such
activities, and (iii) make and implement decisions and allocate available resources necessary or appropriate to advance progress with respect to and complete such activities. 

1.8 “Confidential Information” shall mean, with respect to a party, all information, whether in written, oral or visual
presentation form, of any kind whatsoever (including compilations, data, formulae, models, patent disclosures, procedures, processes, projections, protocols, results of experimentation and testing, specifications, strategies, and techniques), and
all tangible and intangible embodiments thereof of any kind whatsoever (including apparatus, compositions, documents, drawings, machinery, patent applications, records, reports), which is (i) not generally known, (ii) disclosed by such
party to the other party pursuant to and in accordance with the terms of Article 6 of this Agreement and (iii) is identified as confidential, or is otherwise treated by the Disclosing Party as confidential or which the other party has a
reasonable basis to believe is confidential at the time of disclosure. 
 Notwithstanding the foregoing, Confidential
Information of a party shall not include information which the other party can establish by written documentation (a) to have been publicly known prior to disclosure of such information by the Disclosing Party to the other party, (b) to
have become publicly known, without fault on the part of the other party, subsequent to disclosure of such information by the Disclosing Party to the other party, (c) to have been received by the other party at any time from a source, other than the
disclosing party, rightfully having possession of and the right to disclose such information, (d) to have been otherwise known by the other party prior to disclosure of such information by the Disclosing Party to the other party or (e) to have
been independently developed by employees or agents of the other party without access to or use of such information disclosed by the Disclosing Party to the other party. 
 1.9 “Confidentiality Agreement” shall mean the Confidentiality Agreement, dated as of February 12, 2010, between Gen-Probe and PacBio. 

1.10 “Development Plans” shall have the meaning set forth in Section 2.1.2. 

1.11 “Diagnostics” shall mean the in vitro testing of human specimens (including processed human specimens) for the purpose of
medical care of the human from whom the specimen was taken and/or medical care of a human who is the potential recipient of tissue from the human from whom the specimen was taken. For the avoidance of doubt, “medical care” shall include,
by way of example and not of limitation, diagnosis, prognosis, treatment, prevention, or monitoring the progress of any and all possible human disease (including infectious, genetic, traumatic, metabolic, degenerative, and neoplastic disease) as
well as compatibility of donor and recipient with respect to tissue. At Gen-Probe’s sole option, exercisable upon written notice to PacBio, “Diagnostics” shall also mean the in vitro testing of human specimens for the purpose of
medical care of a human who is the potential recipient of human blood, plasma or other blood products from the human from whom the specimen was taken. For the avoidance of doubt, such medical care shall include, by way of example and not of
limitation, diagnosis of possible disease prior to transplant or transfusion, as well as compatibility of donor and recipient with respect to human blood, plasma, and other blood products. 
  

 3 

 1.12 “Disclosing Party” shall have the meaning set forth in Section 6.1

 1.13 “DNA” shall mean any and all forms of deoxyribonucleic acid, including without limitation methylated and other
modified deoxyribonucleic acid sequences and complementary deoxyribonucleic acid synthesized from ribonucleic acid. 
 1.14
“Effective Date” shall mean June 15, 2010. 
 1.15 “Essential Ancillaries” shall mean the reagents and
other consumables (including chips) that are necessary for the effective use of V2 [...***...] or Sample Preparation [...***...], in each case to the extent Commercially Available, respectively, from PacBio or Gen-Probe. 

1.16 “Field” shall mean the field of nucleic acid sequencing products and services expressly marketed for Diagnostics use,
including the parties’ own internal research and development of Products that are intended to be expressly marketed for Diagnostics use. For the avoidance of doubt, solely for purposes of determining whether Gen-Probe and its Affiliates have
complied with the exclusivity obligations set forth in Section 4.1, “nucleic acid sequencing” shall not include methods utilizing multiplexed beads (e.g., [...***...]) or capillary electrophoresis, as such methods are
incorporated in a product offered by Gen-Probe or its Affiliates as of the Effective Date. 
 1.17 “Front End Sample
Preparation” shall mean the isolation, extraction and/or purification of nucleic acid from tissue and bodily fluids obtained directly or indirectly from a human for sequencing, but excluding steps that are integral and specific to the
sequencing process itself. 
 1.18 “Gen-Probe” shall have the meaning set forth in the Preamble hereto. 

1.19 “Gen-Probe Copyrights” shall mean all rights under the copyright laws of any jurisdiction in the world and similar laws
granting rights for written expression, together with all rights commonly referred to as “moral rights,” to the extent that Gen-Probe has the right to grant licenses, immunities or other rights thereunder as of the Effective Date or
thereafter. 
 1.20 “Gen-Probe Derivative IP” shall have the meaning set forth in Section 7.5.1. 

1.21 “Gen-Probe Intellectual Property Rights” shall mean, collectively, the Gen-Probe Copyrights, Gen-Probe Know-How and
Gen-Probe Patent Rights. 
 1.22 “Gen-Probe Inventions” shall have the meaning set forth in Section 7.1. 

1.23 “Gen-Probe Know-How” shall mean information, expertise or data developed by or for Gen-Probe (including formulae,
procedures, protocols, techniques, data and results of experimentation and testing) to the extent that Gen-Probe has the right, under the laws of any jurisdiction in the world, to grant licenses, immunities or other rights thereunder as of the
Effective Date or thereafter. 
 1.24 “Gen-Probe Patent Rights” shall mean patents and patent applications in any
jurisdiction of the world as to which Gen-Probe has an ownership or other licensable interest (other than a license from PacBio pursuant to this Agreement) as of the Effective Date or thereafter, including with respect to any Gen-Probe Invention.

 ***Confidential Treatment Requested 
  

 4 

 1.25 “Initial Development Plan” shall have the meaning set forth in Section 2.1.1.

 1.26 “JAMS” shall have the meaning set forth in Section 9.3. 

1.27 “Joint Copyrights” shall have the meaning set forth in Section 7.3.1. 

1.28 “Joint Intellectual Property” shall have the meaning set forth in Section 7.6. 

1.29 “Joint Inventions” shall have the meaning set forth in Section 7.1. 

1.30 “Joint Know-How” shall have the meaning set forth in Section 7.4. 

1.31 “Licensed GP IP” shall have the meaning set forth in Section 2.4.1. 

1.32 “Licensed PacBio IP” shall have the meaning set forth in Section 2.4.2. 

1.33 “PacBio” shall have the meaning set forth in the preamble hereto. 

1.34 “PacBio Copyrights” shall mean all rights under the copyright laws of any jurisdiction in the world and similar laws
granting rights for written expression, together with all rights commonly referred to as “moral rights,” to the extent that PacBio has the right to grant licenses, immunities or other rights thereunder as of the Effective Date or
thereafter. 
 1.35 “PacBio Derivative IP” shall have the meaning set forth in Section 7.5.1. 

1.36 “PacBio Intellectual Property Rights” shall mean, collectively, the PacBio Copyrights, PacBio Know-How and PacBio Patent
Rights. 
 1.37 “PacBio Inventions” shall have the meaning set forth in Section 7.1. 

1.38 “PacBio Know-How” shall mean information, expertise or data developed by or for PacBio (including formulae, procedures,
protocols, techniques, data and results of experimentation and testing) which relates to the Products to the extent that PacBio has the right, under the laws of any jurisdiction in the world, to grant licenses, immunities or other rights thereunder
as of the Effective Date or thereafter. 
 1.39 “PacBio Patent Rights” shall mean patents and patent applications in
any jurisdiction of the world claiming technology as to which PacBio has an ownership or other licensable interest (other than a license from Gen-Probe pursuant to this Agreement) as of the Effective Date or thereafter, including with respect to any
PacBio Invention. 
 1.40 “Person” shall mean an individual, corporation, partnership, limited liability company,
trust, business trust, association, joint stock company, joint venture, pool, syndicate, sole proprietorship, unincorporated organization, governmental authority or any other form of entity not specifically listed herein, and including Gen-Probe and
PacBio. 
 1.41 “Preferred Access Products” shall mean the products supplied by the parties pursuant to
Section 2.2. 
  

 5 

  
 1.42 “Preferred
Partnership Agreements” shall have the meaning set forth in Section 2.5. 
 1.43 “Product Development Plans”
shall have the meaning set forth in Section 2.1.2. 
 1.44 “Products” shall mean one or more integrated system
products integrating nucleic acid sequencing and Front End Sample Preparation, in each case for use in the Field. 
 1.45
“Proof of Concept” shall mean, with respect to any product, the demonstration of the reasonable technical and commercial efficacy and feasibility of such product for its intended application. 

1.46 “Receiving Party” shall have the meaning set forth in Section 6.1. 

1.47 “Sample Preparation” shall mean the isolation, extraction and/or purification of nucleic acid from tissue and bodily
fluids obtained directly or indirectly from a human for sequencing. 
 1.48 “Sample Preparation [...***...]”
shall mean, individually and collectively, the major [...***...] of Sample Preparation System instruments. 
 1.49
“Sample Preparation Systems” shall mean the reagents, methods, instruments and associated consumables that are used for Sample Preparation, including those that are used for Front End Sample Preparation. 

1.50 “Steering Committee” shall mean the committee comprising representatives of Gen-Probe and PacBio as described in
Section 3.1 below. 
 1.51 “Stock Purchase Agreement” shall have the meaning set forth in the recitals.

 1.52 “Term” shall mean the period set forth in Section 8.1. 

1.53 “Third Generation Sequencing Systems” shall mean the reagents, methods, instruments and associated consumables (including
chips) that are used for single molecule sequencing of nucleic acid, as developed by or on behalf of PacBio including without limitation Single Molecule Real Time (SMRT(TM)) sequencing, the current PacBio RS system and the contemplated PacBio
[...***...] “V2” SMRT DNA sequencing platforms. Gen-Probe acknowledges that, as of the Effective Date, PacBio’s Third Generation Sequencing Systems are designed to sequence DNA (and not RNA). 

1.54 “Third Party” shall mean any Person other than Gen-Probe and PacBio and their respective Affiliates. 

1.55 “V2 [...***...]” shall mean the primary [...***...] contained, or intended to be contained, in the V2 System.

 1.56 “V2 Proof of Concept” shall have the meaning set forth on Exhibit C 

1.57 “V2 [...***...]” shall mean, individually and collectively, the V2 [...***...] and other major sequencing
[...***...] contained, or intended to be contained, in the V2 System. 
 ***Confidential Treatment Requested 

  
 6 

 1.58 “V2 System” shall mean the reagents, methods and instruments that are used
for single molecule sequencing of nucleic acids, as developed by or on behalf of PacBio, in the contemplated “V2” SMRT DNA sequencing platform. 
 ARTICLE 2 
 PRODUCT DEVELOPMENT 

2.1 Development Plans. 
 2.1.1 The initial program for the development of the Products is set forth in Exhibit A (the “Initial Development Plan”). 

2.1.2 It is anticipated that progress made under the Initial Development Plan may necessitate changes to the Initial Development Plan or,
for any Products identified as warranting further development activities, the adoption of additional development plans (the “Product Development Plans,” and, together with the Initial Development Plan, the “Development Plans”).
Product Development Plans may be adopted and the Development Plans may be amended from time to time by the Steering Committee in accordance with the provisions of Article 3. Such actions must be in writing to be effective hereunder. The Development
Plans may include, without limitation: work schedules of activities that specify the development phases; time schedules for completion of such phases; deliverables; key assumptions; itemized budgets by development phase, including agreed costs; test
methods; the timing of reimbursement payments, if any, tied to the completion of milestones; scale-up activities; product specifications; the final activity that completes the Development Plans; and the respective responsibilities of the parties.

 2.1.3 Each party shall designate a contact, which may be a member of the Steering Committee, at their respective offices to
receive and transmit communications concerning the Development Plans. 
 2.1.4 Gen-Probe and PacBio shall conduct their
respective development obligations under the Development Plans diligently and in accordance with the Development Plans and in compliance with applicable laws, regulations and standards for good development practices. Gen-Probe and PacBio each shall
allocate sufficient personnel, equipment, facilities and other resources to the Development Plans to carry out their respective obligations and use Commercially Reasonable Efforts to accomplish the objectives thereof. 

2.1.5 Unless the Steering Committee determines otherwise, each party shall bear its own expenses incurred in performing its obligations
under this Agreement. 
 2.2 Preferred Access Products. 

2.2.1 PacBio shall provide to Gen-Probe access to prototype versions of PacBio’s contemplated Third Generation Sequencing System
product families, through one or more collaborative research projects to be performed using such prototype systems. Such collaborative research projects shall be of nature and scope, and on such terms and conditions, as are mutually agreed by the
parties; provided that [...***...]. 
 ***Confidential Treatment Requested 

 

 7 

 2.2.2 If, during the Term, PacBio initiates a beta testing program for any Third Generation
Sequencing System (whether stand-alone or incorporated into a Product), Gen-Probe shall be permitted to serve as a beta test site for such system, subject to the then-current terms and conditions for such beta test sites that have been established
by PacBio for such Third Generation Sequencing System, consistently applied, and subject to Gen-Probe’s continued fulfillment of its obligations as a beta test site in accordance with such terms and conditions. 

2.2.3 During the Term and thereafter, Gen-Probe shall be entitled to purchase from PacBio, on terms (including warranty terms) that are
commercially reasonable for both parties [...***...], any Third Generation Sequencing System (whether stand-alone or incorporated into a Product) then Commercially Available from PacBio to its customers generally; provided that such
entitlement shall survive a Change of Control of PacBio to the extent any such Third Generation Sequencing System was, immediately prior to such Change in Control: (i) Commercially Available from PacBio to its customers generally or
(ii) (a) in active development by PacBio following a successful Proof of Concept and (b) then intended by PacBio to be Commercially Available to its customers generally in the future (provided, however, that PacBio shall not be obligated
to provide Gen-Probe such access earlier than when such Third Generation Sequencing System is Commercially Available to PacBio’s customers generally). 
 2.2.4 During the Term and thereafter, PacBio shall be entitled to purchase from Gen-Probe, on terms (including warranty terms) that are commercially reasonable for both parties [...***...], any
Sample Preparation System (whether stand-alone or incorporated into a Product) then Commercially Available from Gen-Probe to its customers generally; provided that such entitlement shall survive a Change of Control of Gen-Probe to the extent any
such Sample Preparation System was, immediately prior to such Change in Control: 
 (i) Commercially Available from Gen-Probe to its customers
generally or (ii) (a) in active development by Gen-Probe following a successful Proof of Concept and 
 (b) then intended by Gen-Probe to
be Commercially Available to its customers generally in the future (provided, however, that Gen-Probe shall not be obligated to provide PacBio such access earlier than when such Sample Preparation System is Commercially Available to Gen-Probe’s
customers generally). 
 2.2.5 In addition to, and not in derogation of, Section 2.2.3, during the Term and thereafter,
Gen-Probe shall be entitled to purchase from PacBio, on terms (including warranty terms) that are commercially reasonable for both parties [...***...], any V2 [...***...] (whether stand-alone or embodied in a system) and any Essential
Ancillaries therefor, in each case, then Commercially Available from PacBio; provided that such entitlement to purchase shall survive a Change of Control of PacBio (i) with respect to the V2 [...***...] (and any Essential Ancillaries
therefor), following a successful V2 Proof of Concept and (ii) with respect to any other V2 [...***...] (and any Essential Ancillaries therefor), to the extent any such V2 [...***...] was, immediately prior to such Change in Control:
(a) part of a V2 System 
  
 ***Confidential Treatment Requested 
  

 8 

 
Commercially Available from PacBio or (b) part of a V2 System in active development by PacBio in its Collaboration with Gen-Probe hereunder following a successful Proof of Concept of such V2
[...***...] or V2 System; provided, further that any purchase pursuant to this Section 2.2.5 shall be for the sole purpose of Gen-Probe incorporating such V2 [...***...] into a Product (regardless of whether such Product was
developed under the Collaboration) to be sold in the Field, and in no circumstances for the stand-alone resale of such V2 [...***...]. Upon written request in accordance with Section 10.2 by PacBio to Gen-Probe after expiration or
termination of this Agreement or any such Change in Control, Gen-Probe shall, within ninety (90) days of receipt of such request, provide to PacBio a good faith, commercially reasonable estimate of the likely quantities and delivery dates for
any V2 [...***...] (and any Essential Ancillaries therefor) which Gen-Probe contemplates purchasing pursuant to this Section 2.2.5 over the course of the following [...***...] calendar quarters. Gen-Probe shall continue to provide a
rolling [...***...] calendar quarter estimate, on a quarterly basis, so long as Gen-Probe desires to purchase any V2 [...***...] (and any Essential Ancillaries therefor) pursuant to this Section 2.2.5. 

2.2.6 In addition to, and not in derogation of, Section 2.2.4, during the Term and thereafter, PacBio shall be entitled to purchase
from Gen-Probe, on terms (including warranty terms) that are commercially reasonable for both parties [...***...], any Sample Preparation [...***...] (whether stand-alone or embodied in a system) that is intended to be a part of any
Product contemplated by the Collaboration and any Essential Ancillaries therefor, in each case, then Commercially Available from Gen-Probe; provided that such entitlement to purchase shall survive a Change of Control of Gen-Probe with respect to any
such Sample Preparation [...***...] (and any Essential Ancillaries therefor), to the extent any such Sample Preparation [...***...] was, immediately prior to such Change in Control, an intended part of a Product in active development by
Gen-Probe following a successful Proof of Concept of such Sample Preparation [...***...] or Product; provided, further that any purchase pursuant to this Section 2.2.6 shall be for the sole purpose of PacBio incorporating a Sample
Preparation [...***...] into a Product (regardless of whether such Product was developed under the Collaboration) to be sold in the Field, and in no circumstances for the stand-alone resale of such Sample Preparation [...***...]. Upon
written request in accordance with Section 10.2 by Gen-Probe to PacBio after expiration or termination of this Agreement or any such Change in Control, PacBio shall, within ninety (90) days of receipt of such request, provide to Gen-Probe
a good faith, commercially reasonable estimate of the likely quantities and delivery dates for any Sample Preparation [...***...] (and any Essential Ancillaries therefor) which PacBio contemplates purchasing pursuant to this Section 2.2.6
over the course of the following [...***...] calendar quarters. PacBio shall continue to provide a rolling [...***...] calendar quarter estimate, on a quarterly basis, so long as PacBio desires to purchase any Sample Preparation
[...***...] (and any Essential Ancillaries therefor) pursuant to this Section 2.2.6. 
 2.2.7 The rights and
obligations of the parties under this Section 2.2 shall apply equally to the Affiliates of the parties and the provisions of this Section 2.2 shall be interpreted mutatis mutandis with respect to the Affiliates of the parties, it being
understood that each party may elect to perform any or all of its obligations under this Section 2.2 exclusively through one or more of its Affiliates (e.g., sale of products outside the U.S. via a non-U.S. Affiliate). Each party shall cause
its Affiliates, to the extent applicable, to comply with the provisions of this Section 2.2 as if they were party to this Agreement. 
 ***Confidential Treatment Requested 
  

 9 

 2.3 Access to Information. 

2.3.1 Gen-Probe shall provide PacBio access to relevant Diagnostics market research data that Gen-Probe has generated, or will generate
during the Term, including, without limitation, the [...***...]. 
 2.3.2 PacBio shall provide Gen-Probe access to
relevant Diagnostics market research data that PacBio has generated, or will generate during the Term. 
 2.3.3 Diagnostics
market research data provided by one party to another under this Section 2.3 shall be considered Confidential Information pursuant to Article 6 of this Agreement. Without limiting the foregoing, neither party shall reference or disclose Third
Party study data (including, without limitation, the [...***...]) without the prior written consent of such Third Party. 

2.4 Limited License Grants for Development Plans. 
 2.4.1 License Grant by Gen-Probe. Gen-Probe hereby grants to PacBio a limited, royalty-free, non-exclusive license, for the duration of the Term, to all of the Gen-Probe Intellectual Property Rights
reasonably required for PacBio to perform its obligations under the Development Plans (the “Licensed GP IP”) and solely for such purposes. PacBio shall not have the right to grant sublicenses under such license, without the express prior
written consent of Gen-Probe. 
 2.4.2 License Grant by PacBio. PacBio hereby grants to Gen-Probe a limited, royalty-free,
non-exclusive license, for the duration of the Term, to all of the PacBio Intellectual Property Rights reasonably required for Gen-Probe to perform its obligations under the Development Plans (the “Licensed PacBio IP”) and solely for such
purposes. Gen-Probe shall not have the right to grant sublicenses under such license, without the express prior written consent of PacBio. 
 2.5 Subsequent Agreements. During the Term, the parties shall negotiate in good faith one or more definitive agreements that shall set forth the economic and other terms and obligations of the parties in
furtherance of the continued development, commercialization and regulatory clearance of the Products (the “Preferred Partnership Agreements”). Such Preferred Partnership Agreements shall take into account the technological, commercial,
regulatory and reimbursement findings developed by the parties pursuant to this Agreement. Except as otherwise provided in this Agreement, no party or its Affiliate shall take any steps, during the Term, to commercialize in the Field any Product
developed under the Collaboration or pursue any regulatory clearances in the Field in respect of such Product prior to the execution of a Preferred Partnership Agreement in respect of such Product. 

***Confidential Treatment Requested 
  

 10 

 2.6 Acknowledgements. Notwithstanding the parties’ intentions and obligations,
Gen-Probe and PacBio each: (i) expressly disclaims any representation or warranty that any development activities taken pursuant to this Agreement will be successfully completed and (ii) expressly acknowledges the possibility that any or
all development or commercialization activities may be unsuccessful despite the use of Commercially Reasonable Efforts. Both parties shall plan accordingly. 
 ARTICLE 3 
 GOVERNANCE 

3.1 Steering Committee. 
 3.1.1 The development of Products under the Development Plans shall be coordinated and supervised by the Steering Committee, provided that a Development Plan, and any modification of a Development Plan,
shall not be considered to have been approved unless the budget for a Development Plan or a modified Development Plan shall have been approved in writing by the Chief Financial Officer of each party. The Steering Committee’s duties shall
include (i) determining the priorities of the Collaboration with respect to research activities, which Products to develop and other development matters, (ii) maintaining the Development Plans, including schedules of work and deliverable commitments
by each party, (iii) maintaining an accounting of the expenses borne by each party, (iv) facilitating open communication between the parties on matters relating to the development findings and commercialization of Products in the Field,
and (v) engaging experts as necessary to identify the market, regulatory and reimbursement requirements for integrating Sample Preparation Systems with Third Generation Sequencing Systems. The Steering Committee shall have the power and
authority to appoint joint project teams to oversee and administer activities under this Agreement and shall set the roles and responsibilities for any such project teams. 
 3.1.2 The Steering Committee shall be comprised of three (3) named representatives of Gen-Probe and three (3) named representatives of PacBio. PacBio and Gen-Probe shall each appoint its
respective representatives to the Steering Committee and each party may, from time to time and in its sole discretion, substitute one or more of its representatives by giving notice to the other party of such change. The initial members of the
Steering Committee are set forth on Exhibit B. Each party shall bear its own costs for its representatives’ participation on the Steering Committee. 
 3.2 Meetings. The Steering Committee shall convene not less than once each calendar quarter during the Term. All meetings shall be set at times and places convenient to the members of the Steering
Committee as determined by the chair of the Steering Committee. Each party shall bear its own travel costs in connection with travel to any meetings of the Steering Committee. 
 3.3 Committee Actions. A party’s representatives on the Steering Committee shall collectively have one vote as to all matters. All Steering Committee actions may only be taken by unanimous vote of
the parties. Any approval, determination or other action agreed to by both parties’ representatives shall be the approval, determination or other action of the Steering Committee. Except as may be otherwise specifically set forth in this
Agreement, any matters as to which the Steering Committee cannot reach a unanimous vote shall be presented to the respective executives of the parties for consideration, in accordance with Article 9. 

 

 11 

 3.4 Reports. Within thirty (30) days following each Steering Committee meeting, the
chairperson shall prepare and provide to each party a reasonably detailed written summary report that shall describe any approval, determination or other action by the Steering Committee. 

3.5 Committee Procedures. Meetings of the Steering Committee shall be coordinated and chaired by a representative of one of the parties.
The position of chair shall rotate between the parties each nine (9) months. PacBio shall have the right to appoint a representative to serve as the chair of the Steering Committee for the first nine (9) months of the Term. 

3.6 Steering Committee Action Prior to End of Development Plans. 

3.6.1 In the event that either party reasonably concludes prior to the end of a Development Plan that (i) the development schedule
or development budget for a Product will materially exceed the schedule or budget set forth in such Development Plan, (ii) development will not be able to be conducted or be successfully concluded materially consistently with such Development
Plan, or (iii) based on anticipated market demand or for any other reason that the commercialization of such Product in the Field would not likely be successful, such party shall promptly notify the Steering Committee, which shall discuss all
relevant circumstances and considerations and determine whether any changes are needed to such Development Plan and, if so, make a decision on whether the development work should continue with respect to such Product and whether to modify or
terminate such Development Plan. 
 3.6.2 In the event a Development Plan is terminated under this Section 3.6, the termination
notice shall be effective on the date it is received. Such termination shall not in any way relieve either party of obligations already incurred under the Development Plans prior to termination, including obligations, if any, to reimburse the other
party for any expense determined to be reimbursable by the Steering Committee. 
 3.7 Reports and Records. Once each calendar
quarter prior to the Steering Committee meeting, each party shall prepare a written summary report describing the work performed to date by such party under all active Development Plans and provide such report to the other party. If agreed by the
parties, the foregoing reports may be oral reports given at the Steering Committee meeting. Each party shall maintain complete and accurate records that fully and properly reflect all work done and results achieved by it in the performance of the
Development Plans (including all data in the form required under all applicable laws and regulations). 
 3.8 Inspection of
Records. To the extent reasonably required for the performance of a Development Plan, Gen-Probe and PacBio each shall have the right, during normal business hours and upon reasonable notice, to inspect and copy records of the other party created in
the course of performing such Development Plan, to the extent such records are directly related to, and within the scope of, the Collaboration. The parties shall develop reasonable procedures for requesting and delivering copies of such records to
each other. Each party shall maintain such records and the information of the other party contained therein as Confidential Information hereunder. 
  

 12 

 3.9 Subcontracts. Upon approval of the Steering Committee, which shall not be unreasonably
withheld by either party, each party may subcontract portions of any Development Plan hereunder in the normal course of its business; provided, however, that unless the other party gives its prior written consent, subcontracting with a Third Party
shall not involve the transfer or license (including any sublicense) of the other party’s intellectual property rights and/or Confidential Information. If the other party consents to a subcontractor’s access to Confidential Information of
the other party, the subcontractor shall be required to enter into an agreement including confidentiality terms that are at least as restrictive as the confidentiality terms of Article 6 herein along with provisions for the assignment of inventions
or intellectual property rights arising from the subcontracted work. The subcontracting party shall supervise the work of any subcontractor to ensure, in part, that the subcontractor’s work is in compliance in all material respects with all
requirements of the Development Plans and all applicable laws and regulations. For purposes of this Section 3.9, subcontractors requiring approval of the Steering Committee shall not include subcontractors that provide services on-site of
either party in the ordinary course of such party’s business; provided, however, that such excluded subcontractors shall otherwise be subject to the requirements of this Section 3.9 to the extent they work on any portion of any Development
Plan or have access to the Confidential Information of the other party. 
 3.10 Withdrawal. Notwithstanding anything to the
contrary in this Agreement, either party may, upon thirty (30) days written notice to the other party, withdraw from participation in the Steering Committee, in which case, the Steering Committee shall be dissolved and the parties shall
administer the Agreement without such committee, and shall make such amendments to the Agreement as may be necessary or advisable in connection therewith. All decisions in this Agreement that prior to such notice required the agreement of the
Steering Committee, shall following such notice be subject to the mutual agreement of the parties. 
 ARTICLE 4 

EXCLUSIVITY 
 4.1
Exclusivity. During the Term, neither party, and neither party’s Affiliates, shall (i) jointly develop Products in the Field with any Third Party or (ii) directly or indirectly grant to a Third Party an express license or an express
immunity from suit with respect to any technology used or useful in the Collaboration that would permit such Third Party to develop Products in the Field using such technology either on its own, jointly with such party or with any other Third Party;
provided that a party shall not be precluded from joint development with or out-licensing to a Third Party in respect of a particular Product if: (a) the parties, jointly and in good faith, determine that one or both parties do not have
sufficient capabilities required for the development of a particular Product in the Field, (b) either party requests that the Collaboration include the development of a particular Product in the Field and proposes fair terms with respect to
allocation of development costs, and the other party expressly disclaims any interest in such development, or (c) such a license is granted in good faith in connection with the [...***...]. Subject to the foregoing restrictions and the
other party’s intellectual property rights in a Product, each party shall be permitted to develop, promote, market and sell such Product. 
 ***Confidential Treatment Requested 
  

 13 

 ARTICLE 5 
 REPRESENTATIONS AND WARRANTIES 
 5.1 Representations and Warranties. Each of
Gen-Probe and PacBio hereby represents and warrants as of the Effective Date (except as specifically otherwise indicated below) as follows: 
 5.1.1 Corporate Existence and Power. Such party (a) is a corporation duly organized, validly existing and in good standing under the laws of the state in which it is incorporated; (b) has the
corporate power and authority and the legal right to own and operate its property and assets, to lease the property and assets it operates under lease, and to carry on its business as it is now being conducted; and (c) to its knowledge, is in
compliance with all requirements of applicable law, except to the extent that any noncompliance would not have a material adverse effect on the properties, business, financial or other condition of such party and would not materially adversely
affect such party’s ability to perform its obligations under this Agreement. 
 5.1.2 Authorization and Enforcement of
Obligations. Such party (a) has the corporate power and authority and the legal right to enter into this Agreement and to perform its obligations hereunder and (b) has taken all necessary corporate action on its part to authorize the
execution and delivery of this Agreement and the performance of its obligations hereunder. This Agreement has been duly executed and delivered on behalf of such party, and constitutes a legal, valid and binding obligation, enforceable against such
party in accordance with its terms. 
 5.1.3 Consents. All necessary consents, approvals and authorizations of all governmental
authorities and other Persons required to be obtained by such party in connection with the execution of this Agreement have been obtained on or before the Effective Date. 
 5.1.4 No Conflict. To its knowledge, the execution and delivery of this Agreement and the performance of such party’s obligations hereunder (a) do not conflict with or violate any requirement of
applicable laws or regulations, and (b) do not conflict with, or constitute a default under, any material contractual obligation of such party. 
 5.1.5 No Notice of Infringement. As of the Effective Date, except as otherwise disclosed in writing to the other party, neither Gen-Probe nor PacBio has received any written notice from a Third Party
alleging that any technology of such party expected to be utilized in any Product (each as and to the extent defined as of the Effective Date) to be developed pursuant to this Agreement would infringe the issued patents of such Third Party.

 5.2 DISCLAIMER OF WARRANTIES. NOTHING IN THIS AGREEMENT SHALL BE CONSTRUED AS A REPRESENTATION MADE, OR WARRANTY GIVEN, BY
GEN-PROBE OR PACBIO THAT ANY PATENT WILL ISSUE BASED UPON ANY PENDING PATENT APPLICATION WITHIN THE GEN-PROBE PATENT RIGHTS OR THE PACBIO PATENT RIGHTS, THAT ANY PATENT WITHIN THE GEN-PROBE PATENT RIGHTS OR THE PACBIO PATENT RIGHTS WHICH ISSUES WILL
BE VALID, OR THAT THE USE OF ANY LICENSE GRANTED HEREUNDER, OR THAT THE USE OF ANY GEN-PROBE PATENT RIGHTS OR PACBIO PATENT RIGHTS WILL NOT INFRINGE THE PATENT OR OTHER INTELLECTUAL PROPERTY RIGHTS OF ANY OTHER PERSON. FURTHERMORE, EACH OF GEN-PROBE

  

 14 

 
AND PACBIO DOES NOT MAKE, AND EXPRESSLY DISCLAIMS, ANY REPRESENTATIONS OR WARRANTIES, EXPRESS OR IMPLIED, WITH RESPECT TO THE GEN-PROBE INTELLECTUAL PROPERTY RIGHTS AND THE PACBIO INTELLECTUAL
PROPERTY RIGHTS, RESPECTIVELY, OR TO THE PRODUCTS, INCLUDING WITHOUT LIMITATION, ANY WARRANTY OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE OR NON-INFRINGEMENT. 
 ARTICLE 6 
 CONFIDENTIALITY 

6.1 Confidential Information. For the period commencing on the Effective Date and ending seven (7) years following the expiration or
earlier termination hereof, a party and its Affiliates and their respective directors, officers, employees and consultants (the “Receiving Parties”) shall maintain in confidence the Confidential Information of the other party and its
Affiliates, and shall not disclose to Third Parties the Confidential Information of the other party or its Affiliates (the “Disclosing Parties”) except to Affiliates of the Receiving Parties and their respective directors, officers,
employees and consultants involved in the performance of obligations under this Agreement. To the extent that disclosure to any Third Party is authorized by this Agreement, prior to disclosure, the Receiving Party shall obtain written agreement of
such Third Party to hold in confidence and not disclose, use or grant the use of the Confidential Information of the other party except as expressly permitted under this Agreement. The parties agree that the term of the non-disclosure and non-use
obligations of a Third Party shall be co-extensive with the confidentiality obligations of the parties hereunder. A Receiving Party shall notify the applicable Disclosing Party promptly upon discovery of any unauthorized use or disclosure of the
Disclosing Party’s Confidential Information. Upon the expiration or earlier termination of this Agreement, each Receiving Party shall return to the applicable Disclosing Party all tangible items regarding the Confidential Information of the
Disclosing Party and all copies thereof; provided, however, that a Receiving Party shall have the right to retain one (1) copy for its legal files for the sole purpose of determining its obligations hereunder. Each party shall cause its
Affiliates, to the extent applicable, to comply with the provisions of this Section 6.1 as if they were party to this Agreement. 
 6.2 Terms of this Agreement. For the period commencing on the Effective Date and ending on the expiration or earlier termination hereof, without the prior express written consent of the other party, which
shall not be unreasonably withheld or delayed, neither party nor its Affiliates shall (a) disclose any financial terms or conditions of this Agreement to any Third Party, except as reasonably required in connection with such party’s activities
hereunder and under appropriate confidentiality restrictions; or (b) originate any initial disclosure to any Third Party of the existence or terms of this Agreement; or (c) originate any initial publicity, news release or any other public
announcement (written or oral) relating to this Agreement or the existence of an arrangement among the parties. Notwithstanding the foregoing, the parties shall be allowed to issue mutually agreed upon individual or joint press releases disclosing
the general nature of the Collaboration. Either party shall thereafter be free to disclose any information contained in the public disclosure approved pursuant to this Section 6.2 or which is made without confidentiality restrictions pursuant
to Section 6.3. 
  

 15 

 6.3 Permitted Disclosures. The confidentiality obligations under this Article 6 shall not
apply to the extent that a party is required to disclose information by applicable law, regulation or order of a governmental agency or a court of competent jurisdiction; provided that such party shall provide written notice thereof to the other
party and sufficient opportunity to contest any such disclosure or to request confidential treatment thereof. 
 ARTICLE 7

 DEVELOPED INTELLECTUAL PROPERTY; INTELLECTUAL PROPERTY RIGHTS; 

ENFORCEMENT 
 7.1
Ownership of Inventions. Except as set forth in this Article 7, the entire worldwide right, title and interest in all patentable discoveries, inventions and technology, made or developed in the course of the Collaboration, and in any patents or
patent applications therein, (a) solely by employees of Gen-Probe or others acting on behalf of Gen-Probe (the “Gen-Probe Inventions”) shall, as between Gen-Probe and PacBio, be owned solely by Gen-Probe, (b) solely by employees
of PacBio or others acting on behalf of PacBio (the “PacBio Inventions”) shall, as between PacBio and Gen-Probe, be owned solely by PacBio, and (c) jointly by employees of Gen-Probe or others acting on behalf of Gen-Probe and
employees of PacBio or others acting on behalf of PacBio (the “Joint Inventions”) shall, as between Gen-Probe and PacBio, be owned jointly by Gen-Probe and PacBio. Any dispute as to which party owns any such patentable discoveries,
inventions, technology, patents or patent applications shall be resolved pursuant to Article 9. Each party hereby assigns any such right, title and interest that it may have to the other party to effect the foregoing allocation of ownership rights
and, for such purpose, it shall execute such documents, including assignment agreements and take such steps as reasonably requested by the other party. 
 7.2 Patent Applications and Payment of Related Expenses. 
 7.2.1 PacBio shall be
responsible for and shall control, at its sole discretion and expense, the preparation, filing, prosecution, maintenance and enforcement of all PacBio Patent Rights that are the subject of this Agreement. Gen-Probe shall be responsible for and shall
control, at its sole expense, the preparation, filing, prosecution, maintenance and enforcement of all Gen-Probe Patent Rights that are the subject of this Agreement. 
 7.2.2 The Steering Committee shall establish a strategy for, including the appointment of a party to lead, the preparation, filing, prosecution and maintenance of patent applications and patents for Joint
Inventions. Unless otherwise agreed, the parties shall share equally in the costs, fees and expenses associated with the preparation, filing and prosecution of any patent application claiming a Joint Invention and for the maintenance of such Joint
Inventions. In the event Gen-Probe or PacBio fails or elects not to pay its share of any of the foregoing costs, fees or expenses, it shall assign its entire interest in such Joint Inventions to the other party. Unless otherwise agreed, patent
applications claiming Joint Inventions shall be prepared and prosecuted promptly by mutually acceptable outside counsel. In the preparation and prosecution of patent applications claiming Joint Inventions, each party shall be solely responsible for
communicating its interests to the outside counsel, and no employee of any party shall in any way act as the attorney, agent, or representative of any other party, or otherwise in any way be responsible for representing or protecting the interests
of any other party. All decisions of the outside counsel shall be final and binding. To the extent not inconsistent with this Agreement, 
  

 16 

 
neither party may assert any claims against the other party for any act or omission in the preparation, filing, prosecution, issuance, maintenance, licensing, enforcement or defense of patent
applications or patents issuing therefrom claiming Joint Inventions. 
 7.2.3 The parties shall cooperate with one another to
the extent necessary in connection with the filing of patent applications for their respective inventions and for Joint Inventions. Within a reasonable period of time after a party files any patent application during or after the Term claiming a
Joint Invention conceived during and as a result of the performance of this Agreement, the party filing such an application shall provide the other party with a copy of the application and shall identify with reasonable specificity any Confidential
Information of such other party that may be included therein. The party receiving the copy of the application shall then have one (1) month to review the application and notify the filing party as to whether any of the receiving party’s
Confidential Information is disclosed. If the patent application contains any such Confidential Information or if the filing party shall be required to disclose any Confidential Information pursuant to filing such application, then the filing party
shall withdraw such application (without retaining a residual right to claim priority) before any publication, unless the filing party is given the permission of the other party, which permission shall only be withheld if disclosure of such
Confidential Information has a adverse impact upon the interests of the party having the right to prevent the disclosure of such Confidential Information. 
 7.3 Copyrights. 
 7.3.1 Ownership. Except as set forth in this Article 7, the
entire worldwide right, title and interest in all copyrightable works created in the course of the Collaboration (a) solely by employees of Gen-Probe or others acting on behalf of Gen-Probe shall be owned solely by Gen-Probe, (b) solely by
employees of PacBio or others acting on behalf of PacBio shall be owned solely by PacBio, and (c) jointly by employees of Gen-Probe or others acting on behalf of Gen-Probe and employees of PacBio or others acting on behalf of PacBio (the
“Joint Copyrights”) shall be owned jointly by Gen-Probe and PacBio. 
 7.3.2 Copyright Protection. In order to protect
against infringement of a party’s copyrights or of Joint Copyrights, the parties shall cooperate to apply an appropriate copyright mark to all materials identified by each of the parties as copyrightable materials that are created in the course
of the Collaboration. Each party shall cooperate with the other party, take such actions and execute such documents, as reasonably requested by the other party and at the other party’s expense, to assist the other party in the protection of the
other party’s copyrights. Each party hereby covenants to take no action or make no omission which would constitute an infringement of the other party’s claim of copyright protection with respect to such items. Any dispute as to which party
owns a copyright shall be resolved pursuant to Article 9. Each party hereby assigns any such right, title and interest that it may have to the other party to effect the foregoing allocation of ownership rights and, for such purpose, it shall execute
such documents, including assignment agreements and take such steps as reasonably requested by the other party. 
 7.4 Know-How.
Except as set forth in this Article 7, the entire worldwide right, title and interest in any know-how, trade secrets, information, expertise or data (including formulae, procedures, protocols, techniques, data and results of experimentation and
testing) not otherwise addressed in Sections 7.1 or 7.3.1 and developed or created in the course of the Collaboration (a) solely by 
  

 17 

 
employees of Gen-Probe or others acting on behalf of Gen-Probe shall be owned solely by Gen-Probe, (b) solely by employees of PacBio or others acting on behalf of PacBio shall be owned
solely by PacBio, and (c) jointly by employees of Gen-Probe or others acting on behalf of Gen-Probe and employees of PacBio or others acting on behalf of PacBio (the “Joint Know-How”) shall be owned jointly by Gen-Probe and PacBio.
Any dispute as to which party owns any such know-how, trade secrets, information, expertise or data (including formulae, procedures, protocols, techniques, data and results of experimentation and testing) shall be resolved pursuant to Article 9.
Each party hereby assigns any such right, title and interest that it may have to the other party to effect the foregoing allocation of ownership rights and, for such purpose, it shall execute such documents, including assignment rights and take such
steps as reasonably requested by the other party. 
 7.5 Derivative Intellectual Property. 

7.5.1 Notwithstanding Sections 7.1, 7.3, 7.4 and 7.6, the entire worldwide right, title and interest in any discoveries, inventions,
technology, know-how, trade secrets, information, expertise or data (including formulae, procedures, protocols, techniques, data, results of experimentation and testing), and copyrightable works developed or created in the course of the
Collaboration that are based on, or constitute improvements, enhancements or modifications of, (a) the Licensed GP IP (the “Gen-Probe Derivative IP”) shall be owned solely by Gen-Probe, and (b) the Licensed PacBio IP (the
“PacBio Derivative IP”) shall be owned solely by PacBio; provided that any discoveries, inventions, technology, know-how, trade secrets, information, expertise or data (including formulae, procedures, protocols, techniques, data, results
of experimentation and testing), and copyrightable works developed or created in the course of the Collaboration that use, are based on or incorporate any of, or constitute improvements, enhancements or modifications of both the Licensed GP IP and
the Licensed PacBio IP shall be deemed Joint Intellectual Property, and as applicable, Joint Inventions, Joint Copyrights, or Joint Know-How. 
 7.5.2 Each party shall assign any right, title and interest that it may have to the other party to effect the allocation of ownership rights set forth in Section 7.5.1 and shall cooperate with the
other party, execute such documents, including assignment agreements, and take such steps, as reasonably requested by the other party and at the other party’s expense, to assist the other party in the protection of the other party’s rights
pursuant to Section 7.5.1. 
 7.6 Rights over Joint Intellectual Property. Each party shall own an equal undivided interest in
all Joint Inventions, Joint Copyrights and Joint Know-How (including Diagnostic market requirements developed during the course of performing the Collaboration, to the extent not otherwise included in the foregoing) (collectively, the “Joint
Intellectual Property”) and shall have the right, subject to the provisions of this Agreement, to use, pledge, license, assign or otherwise transfer, its rights in any such Joint Intellectual Property hereunder without the permission, consent
of, or compensation or accounting to, the other party, except to the extent that such use or application of Joint Intellectual Property would require a license from the other party (e.g., under a claim other than that which claims the Joint
Intellectual Property). 
 7.7 No Other Technology Rights. Except as otherwise expressly provided in this Agreement, under no
circumstances shall a party, as a result of this Agreement, obtain any ownership interest or other right in any discovery, invention or other technology, data or information (or any patent, copyright, trademark, or other intellectual property rights
therein) of the other party, including 
  

 18 

 
items transferred by the other party to such party at any time pursuant to this Agreement. There are no implied licenses or rights granted by this Agreement and no implied licenses or rights, and
no licenses or rights by estoppel, shall be created by the parties’ course of performance hereunder. Except as expressly provided in this Agreement, neither party shall be under any obligation to grant to the other party any rights in any
patent, copyright, trademark, or other intellectual property. 
 7.8 Third Party Technology. The Steering Committee shall
discuss Third Party intellectual property rights that may be necessary for the Products. Any such discussions shall, to the extent advisable, take place with legal counsel present in order to preserve legal privileges available to the parties. The
Steering Committee shall consider the costs of acquiring rights in such Third Party intellectual property rights in connection with such Products, allocate the costs as appropriate, and agree upon methods for implementing such cost allocations. The
Steering Committee shall also consider which party shall take the lead in initiating contact with and negotiating with the Third Party. The parties recognize that if the Steering Committee cannot agree on such cost allocation, neither party shall be
under any obligation to separately acquire such rights for use pursuant to this Agreement. 
 7.9 Enforcement. In the event that
either party learns of any Third Party infringement of the Joint Intellectual Property, such party shall promptly provide written notice to the other party, including any evidence of infringement in the possession of the disclosing party.

 7.9.1 Except as set forth in this Section 7.9.1, PacBio and Gen-Probe shall jointly defend and enforce any rights in any
Joint Intellectual Property so that the legal fees, costs and expenses of both parties and any damage awards are shared equally, and with any damages payable to a Third Party or any recoveries from a Third Party resulting from the enforcement or
defense of such rights being shared equally. To the extent necessary, the parties shall appoint a party to lead the defense and enforcement of such rights. The parties shall cooperate fully with one another in legal matters relating to Joint
Intellectual Property, including, but not limited to, providing testimony and executing documents. Both parties have the right, but not the obligation, to participate in any action or proceeding with respect to Joint Intellectual Property by counsel
of its own choice. Absent further agreement of the parties, and subject to Section 7.9.2, each party may elect not to participate in any enforcement action or proceeding and may elect not to pay its shares of the legal fees, costs and expenses
incurred in connection with such action or proceeding. Neither party shall settle any enforcement action or proceeding without the other party’s prior written consent if the proposed settlement will impact the other party’s rights under
the Joint Intellectual Property (e.g., by admitting invalidity). In any event, if both parties are participating in an enforcement action or proceeding, then neither party shall settle such action or proceeding without the other party’s prior
written consent. 
 7.9.2 Subject to 7.9.1, any recovery or other relief for infringement of Joint Intellectual Property shall
first be allocated to reimburse the reasonable and actual expenses incurred in the enforcement process in a manner that results in equal net expenses to PacBio and to Gen-Probe. Any remainder shall be shared equally by PacBio and Gen-Probe if they
both participated (i.e., such that the legal fees, costs and expenses of both parties and any damage awards are shared equally) in the enforcement process. If only one party participated in the enforcement process, the participating party shall be
solely entitled to the relief obtained in the enforcement action or proceeding. 
  

 19 

 7.10 Third Party Infringement. In the event that any Third Party makes a written claim or
demand, or brings an action, suit or proceeding (collectively, an “Action”), against either party, alleging infringement, unauthorized use or misappropriation of such Third Party’s patents, copyrights, technology, other intellectual
property rights or confidential information, and an adverse result from such Action is reasonably likely to have a material impact on the development of any Products in the Field in the good faith determination of such party, such party shall
promptly notify the other party in writing, and provide copies of all materials or papers received by or served on such party from or by such Third Party. For the avoidance of doubt, the parties’ respective obligations to each other with
respect to any Third Party Actions arising out of, in connection with or relating to either party’s sale or use of any Product or Preferred Access Product shall be as set forth in the Preferred Partnership Agreement for such Product or the
supply agreement for such Preferred Access Product, respectively. 
 7.10.1 If an Action relates primarily to the Gen-Probe
Intellectual Property Rights, Gen-Probe shall be primarily responsible for responding to the Action, including controlling any litigation and, unless otherwise agreed by the parties, paying the fees, costs and expenses relating thereto or in
settlement thereof. 
 7.10.2 If an Action relates primarily to the PacBio Intellectual Property Rights, PacBio shall be
primarily responsible for responding to the Action, including controlling any litigation and, unless otherwise agreed by the parties, paying any fees, costs and expenses relating thereto or in settlement thereof. 

7.10.3 The principles of Section 7.9.1 shall apply with respect to any Action that reasonably relates to any Joint Intellectual
Property. 
 7.11 Nothing herein shall require a party to acquire Third Party intellectual property, and the parties acknowledge
that a Third Party claim of infringement is subject to Section 7.8 as to the prospective use of the Third Party technology. In the event that any Third Party intellectual property rights are judicially determined to preclude the manufacture,
use or sale of any Product in the Field and the parties are unable to obtain prospective rights to such Third Party intellectual property rights on commercially reasonable terms, either party shall have the right to terminate development activities
with respect to such Product. The termination of development activities by either party under this Section 7.11 shall mean that the Product shall cease to be an object of development efforts for all purposes under this Agreement and each party
shall be permitted to develop, promote, market and sell such Product, subject to the other party’s intellectual property rights in such Product, notwithstanding any provision of this Agreement to the contrary (including without regard to the
exclusivity provisions of Article 4). 
  

 20 

  
 ARTICLE 8 

TERM AND TERMINATION 
 8.1 Expiration. Unless terminated earlier pursuant to Section 8.2 below, this Agreement shall expire on the earlier of: (i) six (6) months after delivery by PacBio to Gen-Probe of a summary
report establishing successful V2 Proof of Concept and (ii) thirty (30) months after the Effective Date, provided that in no event shall the Agreement expire prior to eighteen (18) months after the Effective Date (the
“Term”). Upon the further written agreement by the parties effected prior to the expiration of the then-applicable Term, PacBio and Gen-Probe may renew this Agreement and extend the original Term. 

8.2 Termination. 
 8.2.1 Breach. Each party may terminate this Agreement after the material breach of this Agreement by the other party, unless the breaching party has cured such breach within sixty (60) days after
notice thereof from the non-breaching party. Any dispute with respect to the right of a party to terminate all or a portion of this Agreement shall be subject to resolution pursuant to Article 9. 

8.2.2 Voluntary Bankruptcy. Each party may terminate this Agreement if the other party shall (a) seek the liquidation, dissolution,
or winding up of itself (other than a liquidation of a solvent company for organizational purposes) or the readjustment of all or substantially all of its debts, (b) apply for or consent to the appointment of, or the taking of possession by, a
receiver, custodian, trustee or liquidator of itself or of all or substantially all of its assets, (c) make a general assignment for the benefit of its creditors, (d) commence a voluntary case under the Bankruptcy Code, (e) file a
petition seeking to take advantage of any other law relating to bankruptcy, insolvency, reorganization, winding-up or readjustment of debts, or (f) adopt any resolution of its Board of Directors or stockholders for the purpose of effecting any
of the foregoing. 
 8.2.3 Involuntary Bankruptcy. Each party may terminate this Agreement if a proceeding or case shall be
commenced without the application or consent of the other party and such proceeding or case shall continue undismissed, or an order, judgment or decree approving or ordering any of the following shall be entered and continue unstayed in effect, for
a period of ninety (90) days from and after the date service of process is effected upon the other party, seeking (a) its liquidation, reorganization, dissolution or winding up, or the readjustment of all or substantially all of its debts,
(b) the appointment of a trustee, receiver, custodian, liquidator or the like of itself or of all or substantially all of its assets, or (c) similar relief under any law relating to bankruptcy, insolvency, reorganization, winding up or
readjustment of debts. 
 8.2.4 Acquisition by a Competitor. Each party may terminate this Agreement if the other party
undergoes a Change of Control whereby (a) the other party is acquired by, merged with or reorganized or consolidated into a competitor of the terminating party (or an Affiliate of such competitor), or (b) the terminating party’s competitor
(or its Affiliate) becomes an Affiliate of the other party. For purposes hereof, (a) PacBio’s “competitors” shall include Life Technologies, Illumina, and F. Hoffman-La Roche, their respective assigns and successors in interest,
and any other entity that competes with PacBio in the DNA sequencing field as of the date of the Change of Control, and (b) Gen-Probe’s “competitors” shall include 

 
 ***Confidential Treatment Requested 

  
 21 

 
[...***...], their respective assigns and successors in interest, and any other entity that competes with Gen-Probe in the molecular Diagnostics field as of the date of the Change of
Control. 
 8.3 Effect of Expiration and Termination. Except to the extent otherwise provided in this Agreement, upon expiration
or termination of this Agreement, all rights and licenses granted hereunder shall terminate. Expiration or termination of this Agreement shall not relieve the parties of any obligation accruing prior to such expiration or termination. The provisions
of this Section 8.3, the provisions of Sections 2.2 (excluding Sections 2.2.1 and 2.2.2), 5.2 and 8.2.1 and Articles 6, 7, 9 and 10 shall survive the expiration or termination of this Agreement, provided, however, that in the case of a termination
prior to expiration of this Agreement, Sections 2.2.3, 2.2.4, 2.2.5 and 2.2.6 shall survive such termination solely in respect of the right of the party entitled to declare a termination to purchase Preferred Access Products of the other party.

 ARTICLE 9 
 DISPUTE RESOLUTION AND GOVERNING LAW 
 9.1 Order. Disputes arising between the
parties relating to the making or performance of this Agreement (including ownership of intellectual property rights, breach of confidentiality, inventorship, etc.) shall be resolved in the following order: (i) by good faith negotiation between
executives of PacBio and Gen-Probe who have authority to fully and finally resolve the dispute; (ii) if necessary, by non-binding mediation at a location acceptable to the parties using a neutral mediator having experience with the industry
(with the costs therefore shared equally); or (iii) as a last resort only, by arbitration of inventorship disputes as provided in Section 9.2, or by arbitration of any other disputes in accordance with Section 9.3. All negotiations
pursuant to this clause shall be treated as Confidential Information in accordance with the provisions of Article 6 of this Agreement, and shall also be treated as compromise and settlement negotiations for purposes of Rule 408 of the Federal Rules
of Evidence and comparable state rules of evidence. 
 9.2 Inventorship Disputes. If the parties are unable to resolve any
dispute regarding inventorship by negotiation or mediation under Section 9.1, they shall submit such dispute to binding arbitration under the C.P.R. Institute for Dispute Resolution Rules for Non-Administered Arbitration of Patent and Trade
Secret Disputes. The arbitrator shall be an independent patent attorney residing in the United States and registered to practice before the United States Patent and Trademark Office. The parties shall request that the arbitrator resolve the
inventorship dispute in accordance with the laws of the United States within three (3) months of his or her appointment. The parties shall supply to the arbitrator documentary evidence of inventorship together with a written statement of their
position not to exceed twenty (20) pages in length within twenty (20) days of the appointment of the arbitrator. Unless the parties agree to rely on affidavits, the arbitrator shall set a hearing at which each party shall have up to eight
(8) hours to present witnesses and to cross examine the witnesses of the other party. If there is a hearing, each party shall provide a statement summarizing the testimony of each witness it may have testify to the other party and the
arbitrator at least fifteen (15) days in advance of the hearing. The parties shall request that the arbitrator’s award be in writing not to exceed twenty (20) pages in length and shall include reasoning in support of the award. The
resolution of the arbitrator shall be final and binding on the parties, without right of appeal. 
 ***Confidential Treatment
Requested 
  

 22 

 9.3 Arbitration Procedure. Except as provided for in Section 9.2, any controversy or
claim relating to, arising out of, or in any way connected to any provision of this Agreement shall be finally resolved by final and binding arbitration in accordance with this Section by a single arbitrator who is a former state or federal judge,
to be conducted in San Francisco, California if initiated by Gen-Probe, or in San Diego, California if initiated by PacBio, or in such other location as mutually agreed by the parties. Unless the parties agree otherwise, the arbitration shall be
conducted by the Judicial Arbitration and Mediation Services, Inc. (“JAMS”), or by any similar arbitration provider who can provide a former judge to conduct such arbitration if JAMS is no longer in existence. JAMS may order a change of
venue upon a showing of good cause by respondent. The decision of the arbitrator shall be final, nonappealable and binding upon the parties, and it may be entered in any court of competent jurisdiction. The arbitrator shall be bound by all rules
relating to the admissibility of evidence, including without limitation, all relevant privileges and the attorney work product doctrine. Discovery shall be permitted in accordance with the rules and procedures of the forum state unless otherwise
agreed to by the parties or ordered by the arbitrator on the basis of strict necessity adequately demonstrated by the party requesting an extension of time. The arbitrator shall have the power to grant equitable relief where applicable under the
law. The arbitrator shall issue a written opinion setting forth his or her decision and the reasons therefor within thirty (30) days after the arbitration proceeding is concluded. The obligation of the parties to submit any dispute arising
under or related to this Agreement to arbitration as provided in this Article 9 shall survive the expiration or earlier termination of this Agreement. 
 9.4 Confidentiality. The existence of and any facts or documents related to any proceedings under Sections 9.1, 9.2, and 9.3 shall be treated as Confidential Information in accordance with the provisions
of Article 6 of this Agreement. Any mediator or arbitrator shall be bound by an agreement containing confidentiality provisions at least as restrictive as those contained in Article 6 of this Agreement. 

9.5 Equitable Considerations. Nothing in this Article 9 shall preclude any party from taking whatever actions are necessary to prevent
immediate, irreparable harm to its interests. 
 9.6 Damages. The parties each agree to waive any right to receive punitive,
indirect, incidental, special or consequential damages (including, but not limited to, loss of profits, revenue, or business) relating in any way to this Agreement; provided, however, that the foregoing waiver shall not apply to any breach of a
party’s obligations of confidentiality under Article 6. 
 9.7 Applicable Law. This Agreement shall be governed by and
construed in accordance with the laws of the State of California, without regard to the conflicts of law principles thereof. The parties agree that the State of California has a substantial relationship to this transaction and each party agrees that
the courts of California shall have exclusive jurisdiction over them and agree to submit to the jurisdiction of such courts. Accordingly, any and all litigation, including without limitation litigation relating to this Agreement, shall be brought
exclusively in the State of California in the state or federal court having subject matter jurisdiction. 
  

 23 

 ARTICLE 10 
 MISCELLANEOUS 
 10.1 Limitation of Liability. 

10.1.1 LIMITATION OF LIABILITY. UNDER NO CIRCUMSTANCES EXCEPT FOR A BREACH OF A PARTY’S OBLIGATIONS OF CONFIDENTIALITY UNDER ARTICLE
6 SHALL A PARTY BE LIABLE FOR PUNITIVE, INDIRECT, INCIDENTAL, SPECIAL OR CONSEQUENTIAL DAMAGES (INCLUDING, BUT NOT LIMITED TO, LOSS OF PROFITS, REVENUE, OR BUSINESS) IN ANY WAY RELATED TO THIS AGREEMENT, OR THE TERMINATION OF THIS AGREEMENT, OR
ARISING OUT OF OR ALLEGED TO HAVE ARISEN OUT OF (i) BREACH OF THIS AGREEMENT, (ii) THE FAILURE BY EITHER PARTY TO DEVELOP ANY PRODUCTS OR PROCESSES IN ACCORDANCE WITH ANY DEVELOPMENT PLAN, (iii) THE FAILURE BY EITHER PARTY TO DEVOTE
THE RESOURCES SPECIFIED IN ANY DEVELOPMENT PLAN, (iv) THE FAILURE BY EITHER PARTY TO COMPLY WITH THE TERMS OF A DEVELOPMENT PLAN, OR (v) ANY EVENT RELATED TO THE CONDUCT OF ANY DEVELOPMENT PLAN. This limitation applies regardless of
whether such damages are sought based on breach of contract, negligence, or any other legal theory. 
 10.2 Notices. Any
consent, notice or report required or permitted to be given or made under this Agreement by one party to the other shall be in writing, addressed to such other party at its address indicated below, or to such other address as the addressee shall
have last furnished in writing to the addressor, and shall be effective: (i) if sent by registered or certified mail in the United States return receipt requested, upon receipt; (ii) if sent by nationally recognized overnight air courier
(such as DHL or Federal Express), two (2) business days after mailing; (iii) if sent by facsimile transmission, with a copy mailed on the same day in the manner provided in clauses (i) or (ii) of this Section 10.2, when
transmitted and receipt is confirmed by telephone or e-mail; and (iv) if otherwise actually personally delivered, when delivered. 
 If to Gen-Probe: Gen-Probe Incorporated 
 10210 Genetic Center Drive 

San Diego, California 92121 
 Attention: President and CEO 
 With a copy to: 

Gen-Probe Incorporated 
 10210 Genetic Center Drive 
 San Diego, California 92121 

Attention: General Counsel 
 and 
  

 24 

 Debevoise & Plimpton LLP 
 919 Third Avenue 
 New York, NY 10022 
 Attention: Andrew L. Bab 
 If to PacBio: Pacific Biosciences of California, Inc.

 1505 Adams Drive 
 Menlo Park, CA 94025 
 Attention: CEO 

With a copy to: 
 Pacific Biosciences of California, Inc. 
 1505 Adams Drive 

Menlo Park, CA 94025 
 Attention: General Counsel 
 10.3 Force Majeure. In the event that a party is
prevented or delayed from fulfilling or performing any of its obligations under this Agreement (other than an obligation to pay money) due to the occurrence of causes beyond the reasonable control of such party, including fires, floods, embargoes,
wars, acts of war (whether war is declared or not), insurrections, riots, civil commotions, strikes, lockouts or other labor disturbances, acts of God or acts, omissions or delays in acting by any governmental authority or the other party, then such
party’s performance shall be excused, and the time for performance shall be extended, for the period of inability or delay due to such occurrence; provided, however, that such party shall have used its Commercially Reasonable Efforts to avoid
such inability or delay, and such party shall have given prompt written notice to the other party of such occurrence. 
 10.4
Assignment. 
 10.4.1 This Agreement may not be directly or indirectly assigned or otherwise transferred, nor, except as
expressly provided hereunder, may any right or obligations hereunder be assigned or transferred by a party (whether voluntarily, by operation of law or otherwise) without the consent of the other party which shall not be unreasonably withheld:
provided, however, that, except as otherwise provided in Section 10.5 below, either party may, without such consent, assign or transfer this Agreement and its rights and obligations hereunder in connection with the transfer or sale of all or
substantially all of its assets related to this Agreement or in the event of its merger, consolidation, other change in control or similar transaction. Any permitted assignee or transferee shall assume all obligations of its assignor or transferor
under this Agreement. Any purported assignment or transfer in violation of this Section shall be void. 
  

 25 

 10.4.2 Assignment by a party of its rights and obligations under this Agreement shall not
relieve that party of its obligations under Articles 6 and 7 hereof. 
 10.5 Change in Control. Each of the parties shall notify
the other party as promptly as possible after any effected Change of Control. The party receiving the notice of Change of Control may require the party subject to the Change of Control to provide adequate assurance of performance of the Agreement.

 10.6 Severability. Each party hereby acknowledges that it does not intend to violate any public policy, statutory or common
laws, rules, regulations, treaty or decision of any government agency or executive body thereof of any country or community or association of countries. Should one or more provisions of this Agreement be or become invalid, the parties shall
substitute, by mutual consent, valid provisions for such invalid provisions, which valid provisions in their economic effect are sufficiently similar to the invalid provisions that it can be reasonably assumed that the parties would have entered
into this Agreement with such provisions. In case such provisions cannot be agreed upon, the invalidity of one or several provisions of this Agreement shall not affect the validity of this Agreement as a whole, unless the invalid provisions are of
such essential importance to this Agreement that it is to be reasonably assumed that the parties would not have entered into this Agreement without the invalid provisions. 
 10.7 Entire Agreement. This Agreement contains the entire understanding of the parties with respect to the subject matter hereof from and after the Effective Date. All express or implied agreements and
understandings, either oral or written heretofore made which are directly related to the subject matter of this Agreement are superceded by this Agreement, except to the extent of rights and obligations pursuant to the Confidentiality Agreement
which had accrued as of the Effective Date. The parties acknowledge that they are also party to the Stock Purchase Agreement and that the provisions of that agreement, or differences between that agreement and this Agreement, shall not influence the
interpretation of this Agreement. This Agreement may be amended, or any term hereof modified, only by a written instrument duly executed by PacBio and Gen-Probe. 
 10.8 Independent Contractors. It is expressly agreed that Gen-Probe and PacBio shall be independent contractors and that the relationship between the parties shall not constitute a partnership, joint
venture or agency. Neither Gen-Probe nor PacBio shall have the authority to make any statements, representations or commitments of any kind, or to take any action, which shall be binding on the other, without the prior consent of the party to do so.

 10.9 No Solicitation. Each party agrees that for a period beginning on the Effective Date and ending on the close of business
on the date two years following the termination or expiration of this Agreement, neither party nor any of its Affiliates shall solicit to employ any officer of the other party or any employee of the other party that is involved in the performance of
this Agreement (which shall include research and development employees and members of the Steering Committee), without obtaining the prior written consent of the other party (it being understood that any newspaper or public solicitation not directed
specifically to such Person shall not be deemed to be a solicitation for purposes of this provision); provided that this Section 10.9 shall not prohibit a party or such party’s Affiliates from discussing employment opportunities with, or
hiring, any officer or employee of the other party involved in the performance of this Agreement who initiates such discussions with such party or such party’s Affiliates. 

 

 26 

 10.10 Waiver. The waiver by a party of any right hereunder or the failure to perform or of a
breach by the other party shall not be deemed a waiver of any other right hereunder or of any other breach or failure by said other party whether of a similar nature or otherwise. 

10.11 Drafting Party; Interpretation. The provisions of this Agreement, and the documents and instruments referred to in the Agreement,
have been prepared, examined, negotiated and revised by each party and their respective lawyers, and no implication shall be drawn and no provision shall be construed against any party by virtue of the purported identity of the drafter of this
Agreement, or any portion of this Agreement. The headings contained in this Agreement are for convenience of reference only, shall not be deemed a part of this Agreement and shall not be referred to in connection with the construction or
interpretation of this Agreement. As used in this Agreement, the words “include” and “including,” and variations of thereof, shall not be deemed to be terms of limitation, but rather shall be deemed to be followed by the words
“without limitation.” The parties acknowledge that they have been represented by counsel and have had the opportunity to conduct due diligence. 
 10.12 Third Parties. None of the provisions of this Agreement shall be for the benefit of or enforceable by any Third Party. 
 10.13 Affiliates. The rights and obligations of each party shall apply to its Affiliates, provided that each party shall be fully responsible for the performance by its Affiliates of such party’s
obligations under this Agreement. 
 10.14 Counterparts. This Agreement may be executed in two or more counterparts, each of
which shall be deemed an original, but all of which together shall constitute one and the same instrument. 
 [REMAINDER OF THIS
PAGE INTENTIONALLY LEFT BLANK] 
  

 27 

 IN WITNESS WHEREOF, the parties have executed this Agreement as of the Effective Date.

 PACIFIC BIOSCIENCES OF CALIFORNIA, INC. 
  

			
	By	 	 /s/ Hugh Martin

		 	Hugh Martin, PhD.
		 	Chairman and Chief Executive Officer
	
	GEN-PROBE INCORPORATED
		
	By	 	 /s/ Eric Tardif

		 	Eric Tardif
		 	Senior Vice President, Corporate Strategy

  

 28 

 EXHIBIT LIST 
 A — Initial Development Plan 
 B — Initial Appointees to Steering Committee 

C — V2 Proof of Concept Criteria 
  

 29 

 EXHIBIT A 
 INITIAL DEVELOPMENT PLAN 
 The parties shall undertake the following activities: 

*making available, through the Steering Committee, all data, expertise, technology and know-how reasonably necessary for each party to perform its
respective obligations under the Collaboration; 
 *defining a potential pilot study regarding the evaluation of Gen-Probe’s Front-End
Sample Preparation technologies combined with PacBio’s sequencing Sample Preparation technologies across multiple sample sources, with the goals of streamlining and optimizing Sample Preparation methodologies within the context of current
market, regulatory and reimbursement requirements and developing the Products for the Diagnostics market; 
 *identifying, through the Steering
Committee, regulatory and reimbursement requirements for an integrated Sample Preparation and Third Generation Sequencing System; 

*identifying the other expected requirements of the Products, including workflow, cost, performance and other requirements, in each case based in part on
customer and key opinion leader input; and 
 *identifying and planning strategies for ensuring clinical adoption of the Products. 

 

 30 

 EXHIBIT B 
 INITIAL APPOINTEES TO STEERING COMMITTEE 
 Gen-Probe Incorporated 

1. [...***...] 
 2. [...***...]

 3. [...***...] 
 Pacific
Biosciences, Inc. 
 1. [...***...] 
 2. [...***...] 
 3. [...***...] 

***Confidential Treatment Requested 
  

 31 

 EXHIBIT C 
 V2 PROOF OF CONCEPT CRITERIA 
 “V2 Proof of Concept” shall mean PacBio’s initial
demonstration, currently targeted to be completed in [...***...], that the V2 System is [...***...], including [...***...] and satisfaction of the milestones set forth below: 

1. Completion of [...***...], including: 

a. Successful completion of [...***...]. 

b. Completion of [...***...]. 
 c.
Completion of the preliminary [...***...], which shall outline the future development pathway and identify any significant remaining technical challenges and the proposed resolution of such challenges. 

d. Successful completion of tests on [...***...] and [...***...], demonstrating preliminary feasibility. Such feasibility tests should
address at least the following risk items: [...***...]. 
 2. Successful completion of the preliminary cost analysis of the
[...***...] and its manufacture, according to the then-current design of the [...***...] and V2 System, demonstrating reasonable technical and commercial efficacy and feasibility of such product for its intended application. 

3. Successful completion of the intellectual property portfolio strategy and plan, including [...***...]. 

4. Completion of risk analysis identifying technical and commercial risks and severity, together with a mitigation plan. 

5. Completion of feasibility for the V2 System as a whole, including top level architecture. 

***Confidential Treatment Requested 
  

 32Exclusive License Agreement - Cornell Research Foundation

 Exhibit 10.8 
 Confidential Treatment Requested by 
 Pacific Biosciences of California,
Inc. 
 EXCLUSIVE LICENSE AGREEMENT 
 THIS AGREEMENT is effective as of February 1, 2004 (“Effective Date”) between Nanofluidics, Inc. (“LICENSEE”), a corporation of the State of Delaware, that has a principal place
of business at 31 Dutch Mill Road, Ithaca, New York 14850, and Cornell Research Foundation, Inc. (“FOUNDATION”), a non-profit corporation of the State of New York, having an office at 20 Thornwood Drive, Suite 105, Ithaca, NY 14850.
FOUNDATION and LICENSEE (individually “Party” and collectively, “Parties”) hereby agree as follows: 
 ARTICLE 1:
INTRODUCTION 
  

	1.1	FOUNDATION is a wholly owned subsidiary of Cornell and holds the ownership interests of patents, trademarks, copyrights, and proprietary materials made by
Cornell’s employees and administers licenses in a manner consistent with the policies of Cornell. 

  

	1.2	The Technology outlined in FOUNDATION dockets: [...***...] have been invented by employees of Cornell University (“Cornell”), assigned to FOUNDATION,
and FOUNDATION has filed for patent protection on such inventions related to Technology 

  

	1.3	LICENSEE desires to obtain the right to develop and to commercialize the Technology. 

 

	1.4	The work leading to the Technology was supported in part by an agency of the United States Government, and FOUNDATION is obligated to comply with United States OMB
Circular A-124 and 37 CFR Part 401. This license is subject to the applicable terms of United States Government regulations concerning Government funded inventions. 

 

	1.5	The Parties agree to the terms and conditions hereinbelow in order to develop the Technology for commercial purposes, and utilize them in the public interest.

 ARTICLE 2: DEFINITIONS 
  

	2.1	“Affiliate” shall mean (1) any corporation or other noncorporate entity owning directly, or indirectly controlling, [...***...] of the stock
normally entitled to vote for election of directors of LICENSEE; (2) any corporation owned or controlled by LICENSEE through ownership of [...***...] of the stock entitled to elect directors or any other entity actually controlled by
LICENSEE, (3) any corporate or noncorporate entity under common control with LICENSEE. 

  

 *** Confidential Treatment Requested 

	2.2	“Applications” shall mean United States Patent Application entitled [...***...] serial number [...***...] filed [...***...],
[...***...] serial number [...***...] filed [...***...], [...***...] filed [...***...] and [...***...] serial number [...***...] filed [...***...] and any other United States patent applications that
may be filed on Technology, and any continuations, continuations-in-part, divisions of these applications, and any foreign patent applications that correspond to United States patent applications. 

 

	2.3	“Patents” shall mean United States Patent Number [...***...] issued [...***...], United States Patent Number [...***...] issued
[...***...], United States Patent Number [...***...] issued [...***...], United States Patent Number [...***...] issued [...***...], any corresponding foreign patent applications, and any patent that issues on
Applications, including any reissues and reexaminations. 

  

	2.4	“Exclusive” shall mean that during the term of this Agreement FOUNDATION will not grant commercial rights to Technology to any other party.

  

	2.5	“Field-of-Use” shall mean [...***...]. 

  

	2.6	“Licensed Territory” shall mean all territories in the world where there are pending Applications or unexpired Patents that have not been declared invalid in
an unappealed decision by a court having jurisdiction 

  

	2.7	“License Year” shall mean each twelve-month period beginning on January 1 and ending on December 31. However, the first License Year (alternatively,
License Year 1) shall commence on the Effective Date and end on December 31 of the same calendar year. 

  

	2.8	“Products” shall mean any product or service which is covered by claims in Applications or Patents or which are made by a process which is covered by claims
in Applications or Patents and any services which is covered by claims in Applications or Patents. 

  

	2.9	“Net Sales” shall mean the gross amount received for sales and other dispositions of Products by LICENSEE, and Sublicensees, to an independent third party on
an arm’s length basis less (i) all trade, quantity, and cash discounts actually allowed on Products, including discounts or rebates to governmental or managed care organizations; (ii) all credits and allowances actually granted on
Products on account of rejection, returns, billing errors, and retroactive price reductions, (iii) charges for freight, insurance and other transport costs related to the delivery of the product; (iv) duties actually paid on Products; and
(v) excise, sale and use taxes, and equivalent taxes or charges actually paid on Products. 

  

	2.10	“Sublicense” shall mean a rights-granting contract with an independent third party other than an Affiliate in which LICENSEE conveys rights granted to
LICENSEE in 4.1 and 4.2 of this Agreement. 

  

 *** Confidential Treatment Requested 

	2.11	“Sublicensees” shall mean any entity granted a Sublicense by LICENSEE, and acceptable to FOUNDATION, under this Agreement. 

 

	2.12	“Technology” shall mean the novel methods, compositions and devices contained in the following FOUNDATION Dockets [...***...] which are described in
United States Patent Number [...***...] issued [...***...], United States Patent Number [...***...] issued [...***...], United States Patent Application Number [...***...] filed [...***...], United States Patent
Application Number [...***...] filed [...***...], United States Patent Application Number [...***...] filed [...***...], United States Provisional Patent Application Number [...***...] filed [...***...], and
United States Provisional Patent Application Number [...***...] filed [...***...] and any other United States patent applications that may be filed on the listed FOUNDATION Dockets, and any other patent applications, continuations,
continuations-in-part, divisions of these applications related thereto, and any foreign patent applications that correspond to United States patent applications. FOUNDATION shall use reasonable efforts to assist LICENSEE in accord with any LICENSEE
funded sponsored research undertaken at Cornell and separately contracted with Cornell’s Office of Sponsored Programs 

  

	2.13	“Valid Claim” shall mean a claim in an issued, unexpired patent or in a pending patent application within the Applications and Patents that (a) has not
been finally cancelled, withdrawn, abandoned or rejected by any administrative agency or other body of competent jurisdiction, (b) has not been revoked, held invalid, or declared unpatentable or unenforceable in a decision of a court or other
body of competent jurisdiction that is unappealable or unappealed within the time allowed for appeal, (c) has not been rendered unenforceable through disclaimer or otherwise, and (d) is not lost through an interference proceeding.

 ARTICLE 3: APPLICATIONS AND PATENTS 
  

	3.1	FOUNDATION shall hold title to all Applications and Patents. 

  

	3.2	FOUNDATION agrees to use reasonable efforts to file and prosecute Applications and maintain Patents. At any time during the term of this Agreement, LICENSEE may elect
in writing to be released from its license in any of the Patents or Applications, in which event LICENSEE shall thereafter have no obligation to reimburse FOUNDATION for any future expenses relating to such Patents or Applications, and FOUNDATION
shall have the option at its sole discretion and expense to file, prosecute, maintain and license to a third party such Patents or Applications. 

  

	3.3	 [...***...] for preparation, filing, prosecution and maintenance of Applications and Patents except for those Applications and

  

 *** Confidential Treatment Requested 

	 	 
Patents for which it has waived its rights, in writing, as described in Section 3.2. Such reimbursable expenses [...***...]. Such expenses shall be paid to FOUNDATION by LICENSEE
within thirty (30) days of receipt of an invoice therefore unless FOUNDATION has otherwise agreed, in writing. LICENSEE shall [...***...] by LICENSEE for reimbursable expenses under this agreement. 

 

	3.4	FOUNDATION shall have final authority over selection of patent attorneys and all decisions concerning filing and prosecution of Applications and maintenance of Patents.
However, FOUNDATION shall keep LICENSEE informed of its filing, prosecution and maintenance activities, such information to include without limitation copies of all documents related to the filing, prosecution and maintenance of Applications and
Patents, and shall give LICENSEE the option to actively participate, including the right to co-counsel, in making major decisions concerning such activities. 

 ARTICLE 4: LICENSE GRANT AND COMMERCIAL EFFORTS 
  

	4.1	Subject to the terms and conditions of this Agreement and to the rights of and obligations to the United States Government as set forth in United States Office of
Management & Budget Circular A-124 or 37 CFR Part 401 et seq., FOUNDATION hereby grants and LICENSEE hereby accepts an EXCLUSIVE right to make, use, sell, offer for sale, lease, import, export or otherwise dispose of Products under
Applications and Patents in Field-of-Use in Licensed Territory for the term of this Agreement as specified in Section 7.1. 

  

	 	(i)	The right of LICENSEE to make Products includes the right to have Products made by contract with third parties within the Licensed Territory. Such contractual
arrangements with third parties shall be subject to and conditioned upon appropriate supervision and quality assurance and control of the third party by LICENSEE and the third party shall be bound in writing to respect all rights of FOUNDATION.

  

	4.2	LICENSEE shall also have the right to grant Sublicenses under this Agreement, [...***...]. LICENSEE agrees to provide FOUNDATION a copy of any Sublicense granted
pursuant to this Article 4. Sublicenses under this Agreement will be considered to be Confidential Information as specified in Section 8.2. Any such Sublicense shall contain provisions that are consistent with all the provisions of this
Agreement which are protective of and beneficial to FOUNDATION. FOUNDATION shall have the right to require that said Sublicense be terminated in the event that a Sublicense materially breaches the above provision. LICENSEE shall be responsible to
FOUNDATION for the [...***...]. LICENSEE shall [...***...] of any up-front Sublicense fees, or other up-front consideration, not including (i) payments made in consideration of the LICENSEE’S issuance of equity, or debt
securities of the LICENSEE and (ii) payments made to LICENSEE in consideration of or as support for research and development activities. LICENSEE’S obligation to pay FOUNDATION’S share of Sublicense consideration described above shall
be considered incurred as of the date on which such Sublicense consideration is received by LICENSEE. 

  

 *** Confidential Treatment Requested 

  

	4.3	FOUNDATION and Cornell retain an irrevocable, nonexclusive, and nontransferable right to practice for their own educational and research purposes, the inventions
claimed in Applications and Patents and such purposes shall include limited, non-commercial collaboration with other non-profit research institutes as long as it does not adversely affect or compete with the business of LICENSEE as determined by an
objective third party acceptable to both parties. 

  

	4.4	Nothing in this Agreement shall be construed to give LICENSEE rights in any inventions currently owned or developed in the future by FOUNDATION or Cornell other than
those explicitly specified in this Agreement. Nothing in this Agreement shall be construed to give FOUNDATION rights in inventions currently owned or developed in the future by LICENSEE other than those explicitly specified in this Agreement.

  

	4.5	The rights granted by this Agreement are to LICENSEE alone and not to any third parties or to any subsidiary or Affiliate of LICENSEE. However, LICENSEE may transfer
this Agreement by way of sale of LICENSEE, through merger, sale of assets and/or sale of stock. LICENSEE shall provide written notice to FOUNDATION of any such transfer. 

 

	4.6	LICENSEE shall use reasonable commercial efforts, consistent with sound and reasonable business practices and judgment, to affect commercialization of Products as soon
as practicable and to maximize sales thereof. [...***...] 

  

	 	(i)	In the event that the FOUNDATION identifies any other markets for DNA sequencing in Licensed Territory and/or other Products and/or geographical area markets as
significant, LICENSEE shall agree in writing to evaluate the potential for commercialization therein itself or through appropriate Sublicense in a timely manner. If LICENSEE elects not to pursue said commercialization in said market(s) or in
FOUNDATION’s sole judgment LICENSEE has failed to evaluate such commercialization, then LICENSEE agrees to Sublicense with reasonable commercial terms to a Sublicensee for said market(s) or terminate this LICENSEE’S rights under this
Agreement only for said significant Products and/or geographical area markets 

  

	 	(ii)	 FOUNDATION may terminate this Agreement if LICENSEE has not [...***...] after the end of the [...***...]. 

 

	4.7	Beginning with the first (1st) License Year, within sixty (60) days after the start of each License Year and until LICENSEE markets Products, LICENSEE shall
make a written annual report to FOUNDATION covering the preceding License Year, regarding the progress of LICENSEE toward commercial use of Products. Such report shall include, at a minimum, information sufficient to enable FOUNDATION to satisfy
reporting requirements of the United States Government and for FOUNDATION to ascertain progress by LICENSEE toward meeting the reasonable commercial efforts of this Article 4. LICENSEE shall provide these reports with the royalty report specified in
Article 5. Such report will be considered to be Confidential Information as specified in Section 8.2. 

  
 ***
Confidential Treatment Requested 

	4.8	LICENSEE shall not use, nor shall LICENSEE permit Sublicensee to use, the names, trademarks and indicia of FOUNDATION or of Cornell, nor the names of any employee,
student or faculty member of FOUNDATION nor of Cornell without prior written approval from FOUNDATION, which will not be unreasonably withheld. 

  

	4.9	LICENSEE shall alone have the obligation to ensure that Products it makes, uses, sells, offers for sale, leases, imports, exports, or otherwise disposes of are not
defective, that Products satisfy all applicable government regulations and that export of Products satisfies government export requirements. 

 ARTICLE 5: PAYMENTS, ROYALTIES, REPORTS AND RECORDS 
  

	5.1	As consideration for entering into this Agreement, [...***...], in the event that LICENSEE [...***...] related series of transactions with total proceeds to
LICENSEE of at least [...***...] (a “Major Financing”) and following such Major Financing, FOUNDATION’S “Equity Ownership” of LICENSEE, which includes the shares of LICENSEE’S non-voting Common Stock then held by
FOUNDATION (or any shares of LICENSEE’S voting common stock issued upon conversion thereof), is less than [...***...] of LICENSEE’S outstanding capital stock (including all outstanding common stock, preferred stock, options or
warrants to purchase common or preferred stock, and any options reserved for issuance under any equity incentive plan, hereinafter referred to as “on a fully diluted basis”); then 

 

	 	(a)	LICENSEE shall issue to the FOUNDATION, pursuant to a common stock purchase agreement in the form attached hereto as Exhibit B, that number of shares of common stock
equal to the number of shares necessary to increase FOUNDATION’S Equity Ownership to [...***...] of LICENSEE’S outstanding capital stock, following such Major Financing, on a fully diluted basis. If the Major Financing exceeds
[...***...], LICENSEE will not issue any shares of common stock to provide an adjustment to FOUNDATION’S Equity Ownership for the amount of the Major Financing in excess of [...***...]; and 

 

	 	(b)	LICENSEE shall grant to FOUNDATION the same registration and information rights granted to the investors in the Major Financing. 

 

	 	(c)	LICENSEE will use its commercially reasonable efforts to cause the common stock issued pursuant to Section 5.1(a) hereof to not be subject to any lock-up periods
that may be required in connection with the LICENSEE’S initial public offering. 

 A Major Financing shall
only include the first financing of LICENSEE that meets the [...***...] proceeds threshold. 
  

	5.2	FOUNDATION hereby consent to any conversion of the non-voting Common Stock held by it to voting Common Stock in connection with the Major Financing.

  

	5.3	FOUNDATION hereby agrees that all previous provisions of, rights granted and covenants made regarding the issuance of the LICENSEE’S capital stock are hereby
waived, released and superseded in their entirety by the provisions of this Section 5 and shall have no further force or effect. 

  

 *** Confidential Treatment Requested 

	5.4	For the license granted hereunder, commencing on the date of the first commercial sale of Product, LICENSEE shall pay or cause to be paid to FOUNDATION a royalty of
[...***...] on Net Sales of Products on a country by country basis [...***...]. In the event that Products incorporate at least one claim described in third party [...***...] (each such third-party [...***...] being defined
as a “Non-Foundation Right”) the royalty shall be (i) the amount of Net Sales for the Products incorporating Non-Foundation Rights, (ii) multiplied by [...***...], and (iii) [...***...]. Such stacking shall
become effective on LICENSEE providing reasonable evidence to FOUNDATION that additional Applications or Patents are applicable to the Product. In the event of a disagreement as to the inclusion of any [...***...], the Parties agree that an
independent neutral party shall be consulted to determine the appropriateness of inclusion of the [...***...] such royalty calculation. 

  

	5.5	 Beginning with the [...***...] License Year and in each License Year thereafter, LICENSEE shall pay FOUNDATION a minimum annual royalty for
that License Year. Payment shall be due within thirty (30) days of the first day of the License Year and [...***...] and the royalty reports required under Section 5.7 should reflect [...***...]. None of the minimum annual
royalties are refundable or applicable to a succeeding License Year. Such minimum annual royalty payments shall be made according to the following schedule and [...***...]: 

 

					
	 License Year
	  	 Payment Due Date
	  	Min. Royalty Payment
	 [...***...]
	  	 [...***...]
	  	[...***...]
	 [...***...]
	  	 [...***...]
	  	[...***...]
	 [...***...]
	  	 [...***...]
	  	[...***...]
	 [...***...]
	  	 [...***...]
	  	[...***...]

  

	5.6	Royalties shall be payable only once with respect to the same unit of Products. 

 

	5.7	 LICENSEE shall provide FOUNDATION with semi-annual written reports, due June 30th and December 31st of each License Year, of all sales, leases or other dispositions of Products by LICENSEE and Sublicensees. In order to
minimize LICENSEE time spent on royalty reports, a brief one-page Royalty Report Form is provided in Exhibit A that will satisfy FOUNDATION’S reporting requirements. The report shall be made within thirty (30) days of the end of each
semiannual period. FOUNDATION agrees to keep the information in these reports confidential, except as may be necessary to maintain an action against LICENSEE for breach of this Agreement. Royalty payments for sales, leases, and other dispositions of
the Products invoiced during a semi-annual period shall accompany the Royalty Report Form for that particular semi-annual period. The Royalty Report Form shall be submitted regardless of whether or not royalties are owed. Payments shall be made in
United States dollars, Conversion from foreign currencies, 

  

 *** Confidential Treatment Requested 

	 	 
if any, shall be based upon the conversion rate published in The Wall Street Journal on the last day of the particular semi-annual accounting period (or on the last business day on which The Wall
Street Journal is published during said semi-annual period) for which royalties are due. Royalty checks shall be made payable to Cornell Research Foundation and mailed to the address specified in section 13.4. 

 

	5.8	LICENSEE shall keep and maintain, and LICENSEE shall require that Sublicensees keep and maintain, any and all records necessary to certify compliance of LICENSEE with
the terms of this agreement, including but not limited to accounting general ledgers, Sublicense and distributor agreements, price lists, catalogs, marketing materials, audited financial statements, income tax returns, sales tax returns, inventory
records, and shipping documents of Products. Such records shall be open to inspection at reasonable times by a certified public accountant chosen by FOUNDATION and acceptable to LICENSEE, which shall not unreasonably withhold such acceptance. Such
inspection shall be made at FOUNDATION’S expense. However, if the results of any audit reveal additional royalties owed to FOUNDATION that differ by more the [...***...] percent) from those royalties already paid, LICENSEE shall also
reimburse FOUNDATION for the costs of the audit. FOUNDATION agrees to hold such records confidential, except as may be necessary to maintain an action against LICENSEE for breach of this Agreement. The records required by this paragraph shall be
maintained and available for inspection for a period of six (6) years following the calendar quarter to which they pertain. This paragraph shall survive termination of this Agreement. 

 

	5.9	LICENSEE shall reimburse FOUNDATION for the expenses specified in Section 3.3 within thirty (30) days of written invoice from FOUNDATION. Such invoice shall
specify the date the expense was incurred, the purpose of the expense (including, as applicable, a summary of patent attorney services giving rise to the expense), and the Applications or Patents to which the expense relates,

  

	5.10	Payments due under Sections 5.1 and 5.5 shall be considered late if not received by the dates specified in Sections 5.1 and 5.5 respectively, whether invoiced or not.
Payments due under Section 5.9, and any other payments due under this Agreement, other than the payments due under Sections 5.1 and 5.5 and royalty payments, shall be considered late if not received within sixty (60) days of the date of
invoice. Royalty payments due under Section 5.7 of this Agreement and payment of FOUNDATION’S share of Sublicense consideration shall become late if not paid within sixty (60) days after the end of the semi-annual in which the payment
obligation was incurred. Late payments [...***...]. 

  

	5.11	LICENSEE agrees to make a written report to FOUNDATION within ninety (90) days after the expiration of this Agreement pursuant to Section 7.1. LICENSEE shall
continue to make reports pursuant to the provisions of this Section 5.7 concerning royalties payable in accordance with Section 5.4 in connection with the sale of Products after expiration of the license, until such time as all such
Products produced under the license have been sold or destroyed. Concurrent with the submittal of each post-termination report, LICENSEE shall pay FOUNDATION all applicable royalties. 

 

 *** Confidential Treatment Requested 

  
 ARTICLE 6: INFRINGEMENT

  

	6.1	In the event that either party determines that a third party is making, using, selling, offering for sale, or importing a product that may infringe Patents, it will
promptly notify the other party in writing. LICENSEE may elect, with the prior written consent of FOUNDATION, to bring suit against such alleged infringer. Such election must be made within thirty (30) days of receipt of said written consent
from FOUNDATION. All recoveries in such suit shall belong to LICENSEE except that LICENSEE may elect to grant FOUNDATION the right to elect to pay up to fifty percent (50%) of the litigation costs and receive a percentage of any recovery equal
to the percentage of litigation costs paid. If such suit involves claims of infringement of Non-Foundation Rights, FOUNDATION’S right of election to pay litigation costs and corresponding rights in recovery shall be limited to 50% multiplied by
the fraction expressed in section 5.4 (iii). FOUNDATION must make such election within thirty (30) days of its receipt of notice that LICENSEE has elected to bring suit. FOUNDATION shall also have the right to choose to be represented by
separate counsel in any such suit at its own expense. Such expense for separate counsel shall not be considered as part of “litigation costs” for purposes of determining FOUNDATION’S share of any recovery in accordance with the
sentence above. If LICENSEE elects not to bring a suit against the alleged infringer, it shall promptly notify FOUNDATION of that fact and FOUNDATION shall have the right to commence such actions at its own cost and expense, in which case any
recoveries shall belong to FOUNDATION. In such suits by FOUNDATION, LICENSEE shall have rights of participation and recovery that are the same as FOUNDATION rights as provided above when LICENSEE elects to sue, except in this case the fraction
expressed in section 5.4 (iii) shall not be applied. 

  

	6.2	Regardless of which party controls a suit brought against an infringer, both parties shall participate in any settlement discussions and each will be a signatory to any
settlement agreement. 

 ARTICLE 7: TERM AND TERMINATION 

 

	7.1	This Agreement shall commence on Effective Date, and shall continue as a Field-of-Use Exclusive license until the last of all Patents has either expired or been
invalidated in an unappealed decision by a court having jurisdiction so long as LICENSEE’S covenants under the Agreement are being performed and the LICENSEE is in good standing, and provided this Agreement is not earlier terminated as provided
for herein. 

  

	7.2	FOUNDATION may terminate this Agreement if LICENSEE: 

  

	 	(i)	is in default in payment of license fees, royalties or cost reimbursements or in providing reports; 

 

	 	(ii)	is in material breach of any provision of this Agreement; 

  

	 	(iii)	provides any false report; 

  

	 	(iv)	if LICENSEE does not [...***...] prior to [...***...]; 

  

	 	(v)	 has not [...***...] after the end of the [...***...] ; 

  
 ***
Confidential Treatment Requested 

	 	(vi)	if LICENSEE fails to provide written notice to FOUNDATION for the transfer of this Agreement upon the sale of LICENSEE in accordance to Section 4.5 or for a
Sublicense of this Agreement in accordance with Section 4.2 

 and LICENSEE fails to remedy any such default,
breach, or false report within sixty (60) days after receiving written notice thereof by FOUNDATION. 
  

	7.3	LICENSEE may terminate the license granted hereunder at any time upon sixty (60) days notice to FOUNDATION. FOUNDATION agrees that any expenses initiated by
FOUNDATION during the sixty (60) day termination period will not be LICENSEE’S financial obligation although all other obligations under this Agreement shall continue to accrue during the sixty (60) day notice period, including the
obligation to make any payments due under this Agreement. 

  

	7.4	Upon termination of this Agreement for any reason, including the end of term as specified above, all rights and obligations under this Agreement shall terminate, except
those that have accrued prior to termination and except as specified in this Agreement. 

 ARTICLE 8: PUBLICATION AND
CONFIDENTIALITY 
  

	8.1	It is the policy of FOUNDATION and Cornell to promote and safeguard free and open inquiry by faculty, students and others. To further this policy, FOUNDATION and
Cornell shall retain the right to publish information described in Applications and Patents. 

  

	8.2	Both parties agree to keep any information identified as confidential by the disclosing party confidential using methods at least as stringent as each party uses to
protect its own confidential information, except as may be necessary to maintain an action against LICENSEE for breach of this Agreement or to audit LICENSEE as specified under Section 5.8. “Confidential Information” shall include the
progress report required under Section 4.7 and any other information marked confidential or accompanied by correspondence indicating such information is confidential exchanged between the parties hereto. The confidentiality and use obligations
set forth above apply to all or any part of the Confidential Information disclosed hereunder except to the extent that: 

  

	 	(a)	LICENSEE or FOUNDATION can show by written record that it possessed the information prior to its receipt from the other party; 

 

	 	(b)	The information was already available to the public or became so through no fault of the LICENSEE or FOUNDATION; 

 

	 	(c)	The information is subsequently disclosed to LICENSEE or FOUNDATION by a third party that has the right to disclose it free of any obligations of confidentiality; or

  

	 	(d)	Five years have elapsed from the expiration of this Agreement. 

 ARTICLE 9: ARBITRATION AND JUDICIAL REMEDIES 
  

	9.1	If a controversy arises under or related to this Agreement, and any disputed claim by either party against the other under this Agreement excluding any dispute relating
to patent validity or infringement arising under this Agreement, the parties shall endeavor to resolve such controversy or dispute by mutual, good faith conciliation and mediation and, failing that, may mutually agree to settle the controversy or
dispute by arbitration in accordance with the Licensing Agreement Arbitration Rules of the American Arbitration Association. 

	 	(i)	Upon request by either party, arbitration will be by a third party arbitrator mutually agreed upon in writing by LICENSEE and FOUNDATION within thirty (30) days of
such arbitration request. If the parties fail to mutually agree upon said third party arbitrator within the allotted thirty days, then the arbitration will be by a panel of three arbitrators comprising one arbitrator selected by each party within a
further thirty (30) day period and a third arbitrator selected by the preceding two arbitrators. If one party fails to select an arbitrator within the allotted thirty day period, then said arbitration panel will consist solely of the arbitrator
chosen by the other party. 

  

	 	(ii)	The parties shall be entitled to discovery in like manner as if the arbitration were a civil suit in the New York Superior Court. The Arbitrator may limit the scope,
time and/or issues involved in discovery. 

  

	 	(iii)	Any arbitration shall be held at Ithaca, NY, unless the parties hereto mutually agree in writing to another venue. 

 

	9.2	FOUNDATION reserves the right and power to proceed with direct judicial remedies against LICENSEE without conciliation, mediation or arbitration for breach of the
royalty payment and sales reporting provisions of this Agreement after giving written notice of such breach to LICENSEE followed by an opportunity period of thirty (30) days in which to cure such breach. In collecting overdue royalty payments
and securing compliance with reporting obligations, FOUNDATION may use all judicial remedies available. 

 ARTICLE 10:
INDEMNIFICATION 
  

	10.1	LICENSEE agrees to indemnify and hold harmless FOUNDATION and Cornell and their respective trustees, officers, employees, students, and agents against any and all
claims for death, illness, personal injury, property damage, damages, expenses, losses and improper business practices arising out of (i) the manufacture, use, sale, or other disposition of Patents or Products by LICENSEE, Sublicensee, or their
customers, (ii) a third party’s use of a Products purchased, leased, or otherwise acquired from LICENSEE or Sublicensee, (iii) a third party’s manufacture or provision of a Products at the request of LICENSEE or Sublicensee.

  

	10.2	FOUNDATION shall not be liable for any indirect, special, consequential, or other damages whatsoever, whether grounded in tort (including negligence), strict liability,
contract or otherwise. FOUNDATION shall not have any responsibilities or liabilities whatsoever with respect to Products. 

  

	10.3	LICENSEE and Sublicensee shall at all times comply, through insurance or self-insurance, with all statutory workers’ compensation and employers’ liability
requirements covering any and all employees with respect to activities performed under this Agreement. 

	10.4	LICENSEE agrees to obtain and maintain insurance against liability, damage, destruction and loss comparable to that which is maintained by companies in similar
businesses at similar stages in their growth. 

	10.5	The provisions of this article shall survive termination of this Agreement. 

 ARTICLE 11: WARRANTIES AND LIMITATIONS 
  

	11.1	FOUNDATION and LICENSEE each represent and warrant that they have the right to enter into this Agreement. FOUNDATION warrants that it has the right to convey to
LICENSEE the rights granted under this Agreement. 

  

	11.2	FOUNDATION warrants that is the owner of Applications and Patents. 

  

	11.3	FOUNDATION makes no representation or warranty that Applications will result in issued Patents. 

 

	11.4	FOUNDATION makes no representations or warranties concerning the validity or scope of Patents. 

 

	11.5	FOUNDATION does not warrant that Products made, used, sold, leased, imported, exported or otherwise disposed of under the license of this Agreement is or will be free
from infringement of patents of third parties. 

  

	11.6	Nothing herein shall be construed as granting by implication, estoppel, or otherwise any licenses or rights under patents or other rights of FOUNDATION or Cornell or
other persons other than Patents, regardless of whether such patents or other rights are dominant or subordinate to any Patents. 

  

	11.7	FOUNDATION is under no obligation to furnish any technology or information other than that described and claimed in Applications and Patents. 

 

	11.8	Nothing herein shall be construed to grant LICENSEE rights under any applications or patents other than Applications and Patents. 

 

	11.9	FOUNDATION does not make any representations, extend any warranties of any kind, express or implied, or assume any responsibility whatever concerning the manufacture,
use, or sale, lease or other disposition by LICENSEE or its vendees or transferees of Products. 

  

	11.10	Except as expressly set forth in this Agreement, FOUNDATION MAKES NO REPRESENTATIONS AND EXTENDS NO WARRANTIES OF ANY KIND, EITHER EXPRESS OR IMPLIED. THERE ARE NO
EXPRESS OR IMPLIED WARRANTIES OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE, OR THAT THE USE OF PRODUCTS WILL NOT INFRINGE ANY PATENT, COPYRIGHT, TRADEMARK, OR OTHER RIGHTS OR ANY OTHER EXPRESS OR IMPLIED WARRANTIES.

 ARTICLE 12: MARKING 
  

	12.1	Prior to the issuance of patents on the Applications, LICENSEE shall mark, and agrees to require that Sublicensees shall mark, Products (or their containers or labels)
made, sold, leased, imported, exported or otherwise disposed of by it under the license granted in this Agreement with the words “Patent Pending,” and following the issuance of one or more Patents, with the numbers of Patents.

 ARTICLE 13: MISCELLANEOUS PROVISIONS 
  

	13.1	Terms in this Agreement which appear capitalized, other than the names of the parties and article headings, have the meanings given in Article 2 and retain those
meanings whether used in the singular or plural. 

  

	13.2	This Agreement shall be binding upon and be to the benefit of the Parties hereto and their heirs, successors and assignees. However, neither Party shall assign this
Agreement, in whole or in part, without the written consent of the other. 

  

	13.3	All issues and questions concerning the construction, validity and interpretation of this Agreement and the Schedules and Exhibits hereto shall be governed by, and
construed in accordance with, the laws of the State of New York without giving effect to any choice of law or conflict of law rules or provisions (whether of the State of New York or any other jurisdiction) that would cause the application of the
laws of any jurisdiction other than the State of New York. In furtherance of the foregoing, the internal law of the State of New York shall control the interpretation and construction of this Agreement (and all Schedules and Exhibits hereto), even
though under that jurisdiction’s choice of law or conflict of law analysis, the substantive law of such other jurisdiction would ordinarily apply. The parties hereto hereby irrevocably and unconditionally submit to the exclusive jurisdiction of
any State court sitting in Tompkins County, State of New York or Federal court sitting in Syracuse, New York over any suit, action or proceeding arising out of or relating to this Agreement and agree that no such suit, action or proceeding shall be
brought in any other court, forum or jurisdiction. The parties hereto hereby irrevocably and unconditionally waive any objection to the laying of venue of any such suit, action or proceeding brought in any such court and any claim that any such
suit, action or proceeding brought in any such court has been brought in an inconvenient forum. 

  

	13.4	All notices required or permitted hereunder shall be in writing and be served on the parties at the addresses set forth below. Any such notices shall be either
(a) sent by a nationally recognized overnight courier, in which case notice shall be deemed delivered when delivery is made according to the records of such courier, (b) sent by facsimile, in which case notice shall be deemed delivered
upon receipt of confirmation of transmission of such facsimile notice, or (c) sent by personal delivery, in which case notice shall be deemed delivered upon receipt. Any notice by facsimile or personal delivery and delivered after 5:00 p.m.,
Eastern Daylight Time, shall be deemed received on the next Business Day. A party’s address may be changed by written notice to the other parties; provided, however, that no notice of a change of address shall be affected until actual receipt
of such notice. 

 In the case of FOUNDATION: 

President 

Cornell Research Foundation, Inc. 
 20 Thornwood Drive, Suite 105 
 Ithaca, NY 14850 

In the case of LICENSEE: 
 President 
 Nanofluidics, Inc. 

31 Dutch Mill Road 
 Ithaca, NY 14850 
  

	13.5	No term or provision of this Agreement shall be waived and no breach excused unless such waiver or consent shall be in writing and signed by the party claimed to have
waived or consented. No waiver of a breach shall be deemed to be a waiver of a different or subsequent breach. 

  

	13.6	This Agreement may not be modified, changed or terminated orally. No change, modification, addition or amendment shall be valid unless in writing and signed by the
parties hereto. 

  

	13.7	In the event any provision of this Agreement is determined to be invalid or unenforceable, the remaining provisions shall remain in full force and effect.

  

	13.8	This Agreement constitutes and contains the entire agreement of the parties respecting its subject matter and supersedes any and all prior negotiations, correspondence,
understandings and agreements, whether written or oral, between the parties respecting its subject matter. 

 IN WITNESS of this
Agreement, FOUNDATION and LICENSEE have caused this Agreement to be executed by their duly authorized officers on the dates indicated. 
  

							
	Cornell Research Foundation, Inc.	  	Nanofluidics, Inc.
				
	By:	  	 /s/ Richard S. Cahoon
	  	By:	  	 /s/ Stephen W. Turner

		  	Richard S. Cahoon	  		  	Stephen W. Turner
				
	Title:	  	 Senior Vice President
	  	Title:	  	 President

				
	Date:	  	 March 2, 2004
	  	Date:	  	 March 2, 2004

 EXHIBIT A - ROYALTY REPORT 
 Report royalty payment information to the Cornell Research Foundation, Inc (CRF) using the report format or facsimile attached to these instructions. This minimal information must be provided in order to
correctly record royalty related events required by your license agreement with CRF. 
 Use a separate report to record royalty information for
each license agreement. For each licensee agreement, report royalty sales by CRF docket number, which identifies the technology. List each contributing technology if more than one technology is used to produce a royalty generating process/product.
This level of detail permits evaluation of the use of each technology under license with your company. 
 Submit this information along with
appropriate payment to: 
 Cornell Research Foundation, Inc. 
 ATTN: Finance and Accounting 
 20 Thornwood Drive, Suite 105 

Ithaca, NY 14850 
 (607) 257-1081

www.crf.cornell.edu 
 For your
convenience, payments may be made by FEDWIRE or ACH to: 
 [...***...] 
 Account: [...***...], ABA: [...***...] 
  

 *** Confidential Treatment Requested 

 ROYALTY REPORT – [licensee NAME] 

 

							
	LICENSEE NAME:	 	  
	  	CRF LICENSE NUMBER:	 	  

 

					
	REPORTING PERIOD:	 	  
	  	

 Individual to contact concerning this information: 

 

									
	Name:	 	  
	  	Phone # or email ID:	  	  
	  	

 For each product/item subject to a royalty payment provision, provide the following information as applicable.

  

					
	 PRODUCT/ITEM:
	 	  
	 	

  

															
	 CRF Docket Number
	 	 Country
	 	 Number of

Units/Products Sold
	 	 Gross Sales By

Country
	 	 Net Sales By

Country
	 	 Royalty Rate
	 	 Less Minimum Royalty

Payment Made
	 	 Net Royalty

Payment Made

		 		 		 		 		 		 		 	
		 		 		 		 		 		 		 	
		 		 		 		 		 		 		 	
		 		 		 		 		 		 		 	
		 		 		 		 		 		 		 	
		 		 		 		 		 		 		 	
		 		 		 		 		 		 		 	
		 		 		 		 		 		 		 	
		 		 		 		 		 		 		 	
		 		 		 		 		 		 		 	
		 		 		 		 		 		 		 	
		 		 		 		 		 		 		 	
		 		 		 		 		 		 		 	
		 		 		 		 		 		 		 	
		 		 		 		 		 		 	 Total Payment
	 	

  

 16

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00179-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00179-of-00352.parquet"}]]